Identification

Name
Dronedarone
Accession Number
DB04855
Type
Small Molecule
Groups
Approved
Description

Dronedarone is a sinus rhythm controller for management of paroxysmal or persistent atrial fibrillation. Classified as a Class III antiarrhythmic but displays properties of all four Vaughan-Williams classes, dronedarone blocks a multitude of channels (sodium, potassium, calcium), and demonstrates antiadrenergic properties. Chemically, it is a benzofuran derivative. FDA approved on July 1, 2009.

Structure
Thumb
Synonyms
  • N-(2-Butyl-3-(4-(3-(dibutylamino)propoxy)benzoyl)-5-benzofuranyl)-methanesulfonamide
  • N-(2-Butyl-3-(P-(3-(dibutylamino)propoxy)benzoyl)-5-benzofuranyl)methanesulfonamide
  • SR 33589
  • SR 33589b
External IDs
SR-33589 / SR33589
Product Ingredients
IngredientUNIICASInChI Key
Dronedarone HydrochlorideFA36DV299Q141625-93-6DWKVCQXJYURSIQ-UHFFFAOYSA-N
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
MultaqTablet, film coated400 mg/1OralSanofi Aventis2009-07-01Not applicableUs
MultaqTablet, film coated400 mg/1OralSanofi Winthrop Industries2009-07-01Not applicableUs
MultaqTablet, film coated400 mgOralSanofi Aventis Groupe2009-11-26Not applicableEu
MultaqTablet400 mgOralSanofi Aventis2009-09-28Not applicableCanada
MultaqTablet, film coated400 mg/1OralCardinal Health2009-07-01Not applicableUs
MultaqTablet, film coated400 mgOralSanofi Aventis Groupe2009-11-26Not applicableEu
MultaqTablet, film coated400 mg/1OralPhysicians Total Care, Inc.2010-02-23Not applicableUs
MultaqTablet, film coated400 mgOralSanofi Aventis Groupe2009-11-26Not applicableEu
MultaqTablet, film coated400 mgOralSanofi Aventis Groupe2009-11-26Not applicableEu
International/Other Brands
Multaq
Categories
UNII
JQZ1L091Y2
CAS number
141626-36-0
Weight
Average: 556.756
Monoisotopic: 556.297093218
Chemical Formula
C31H44N2O5S
InChI Key
ZQTNQVWKHCQYLQ-UHFFFAOYSA-N
InChI
InChI=1S/C31H44N2O5S/c1-5-8-12-29-30(27-23-25(32-39(4,35)36)15-18-28(27)38-29)31(34)24-13-16-26(17-14-24)37-22-11-21-33(19-9-6-2)20-10-7-3/h13-18,23,32H,5-12,19-22H2,1-4H3
IUPAC Name
N-(2-butyl-3-{4-[3-(dibutylamino)propoxy]benzoyl}-1-benzofuran-5-yl)methanesulfonamide
SMILES
CCCCN(CCCC)CCCOC1=CC=C(C=C1)C(=O)C1=C(CCCC)OC2=C1C=C(NS(C)(=O)=O)C=C2

Pharmacology

Indication

Management of paroxysmal or persistent atrial fibrillation via restoration of normal sinus rhythm.

Associated Conditions
Pharmacodynamics

Dronedarone is a non-iodinated benzofuran derivative for the management of paroxysmal or persistent atrial fibrillation. Dronedarone inhibits human atrial sodium currents (INa) in a dose dependent manner in which a concentration of 0.3 μM is sufficient to completely inhibit INa. Chemically it is related to amiodarone, a popular antiarrhythmic the use of which is limited to toxicity due its high iodine content (pulmonary fibrosis, thyroid disease) as well as by liver disease. Dronedarone lacks the iodine, and is expected to have less toxicity, yet it displays amiodarone-like class III antiarrhytmic activity in vitro and in clinical trials. Despite this advantage over amiodarone, clinical trials of dronedarone have shown that it may increase risk of stroke and mortality from cardiovascular causes and arrhythmia. Furthermore, amiodarone more potently effects action potential and refractory periods than dronedarone.

Mechanism of action

The antiarrhythmic effect of dronedarone may be due to at least two major actions. It prolongs the duration of action potential and refractory period in myocardial tissue via inhibition of sodium and potassium channels. Via inhibition of calcium channels and blockage of beta1-adrenergic receptors, a decrease in AV conduction and sinus node function can be observed. Dronedarone can also cause an increase in blood pressure by inhibition of alpha1-adrenergic receptors.

TargetActionsOrganism
UAlpha-1A adrenergic receptor
antagonist
Human
UAlpha-1B adrenergic receptor
antagonist
Human
UAlpha-1D adrenergic receptorNot AvailableHuman
UAlpha-2A adrenergic receptorNot AvailableHuman
UAlpha-2B adrenergic receptorNot AvailableHuman
UAlpha-2C adrenergic receptorNot AvailableHuman
UBeta-1 adrenergic receptorNot AvailableHuman
UPotassium voltage-gated channel subfamily H member 2Not AvailableHuman
UVoltage-dependent L-type calcium channel subunit alpha-1CNot AvailableHuman
UVoltage-dependent L-type calcium channel subunit alpha-1DNot AvailableHuman
UVoltage-dependent L-type calcium channel subunit alpha-1FNot AvailableHuman
UVoltage-dependent L-type calcium channel subunit alpha-1SNot AvailableHuman
UVoltage-dependent L-type calcium channel subunit beta-1Not AvailableHuman
UVoltage-dependent L-type calcium channel subunit beta-2Not AvailableHuman
UVoltage-dependent L-type calcium channel subunit beta-3Not AvailableHuman
UVoltage-dependent L-type calcium channel subunit beta-4Not AvailableHuman
USodium channel protein type 1 subunit alpha
inhibitor
Human
UPotassium channel subfamily K member 2
inhibitor
Human
Absorption

Because of presystemic first pass metabolism the absolute bioavailability of dronedarone without food is low, about 4%. It increases to approximately 15% when dronedarone is administered with a high fat meal. After oral administration in fed conditions, peak plasma concentrations of dronedarone and the main circulating active metabolite (N-debutyl metabolite) are reached within 3 to 6 hours. After repeated administration of 400 mg twice daily, steady state is reached within 4 to 8 days of treatment. The steady state Cmax and exposure of the main N-debutyl metabolite is similar to that of the parent compound.

Volume of distribution

When intravenously administered, the volume of distribution is 1400 L.

Protein binding

Dronedarone and its N-debutyl metabolite is >98% protein bound - mainly to albumin.

Metabolism

Majority of dronedarone is eliminated by first-pass metabolism in the liver by CYP3A4 enzymes (>84%). Dronedarone is also metabolized by CYP2D6 to a lesser extent. N-DBD is its active metabolite (1/10 to 1/3 potency of dronedarone) which can penetrate the blood-brain barrier, placenta, and is excreted in breast milk. However, it does not significantly accumulate in plasma or tissue.

Route of elimination

6% of the dose was excreted in the urine, mainly as metabolites (no unchanged compound excreted in urine), and 84% was excreted in feces, mainly as metabolites.

Half life

Elimination half-life: 13-19 hours

Clearance

Plasma clearance = 130-150 L/h.

Toxicity

Most common adverse reactions (≥2%) are diarrhea, nausea, abdominal pain, vomiting, and asthenia.

Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
4-MethoxyamphetamineThe metabolism of 4-Methoxyamphetamine can be decreased when combined with Dronedarone.Experimental, Illicit
AbemaciclibThe metabolism of Abemaciclib can be decreased when combined with Dronedarone.Approved, Investigational
AbirateroneThe serum concentration of Dronedarone can be increased when it is combined with Abiraterone.Approved
AcebutololDronedarone may increase the bradycardic activities of Acebutolol.Approved, Investigational
AcenocoumarolThe serum concentration of Acenocoumarol can be increased when it is combined with Dronedarone.Approved, Investigational
AcepromazineDronedarone may increase the antihypertensive activities of Acepromazine.Approved, Vet Approved
AcetaminophenThe metabolism of Acetaminophen can be decreased when combined with Dronedarone.Approved
Acetyl sulfisoxazoleThe metabolism of Dronedarone can be decreased when combined with Acetyl sulfisoxazole.Approved, Vet Approved
AcetylcholineThe metabolism of Acetylcholine can be decreased when combined with Dronedarone.Approved
AdinazolamThe metabolism of Adinazolam can be decreased when combined with Dronedarone.Approved
AdrafinilDronedarone may decrease the vasoconstricting activities of Adrafinil.Withdrawn
AfatinibThe serum concentration of Afatinib can be increased when it is combined with Dronedarone.Approved
AgmatineDronedarone may decrease the vasoconstricting activities of Agmatine.Experimental, Investigational
AjmalineThe metabolism of Ajmaline can be decreased when combined with Dronedarone.Approved, Investigational
AlbendazoleThe metabolism of Albendazole can be decreased when combined with Dronedarone.Approved, Vet Approved
AlclometasoneThe metabolism of Alclometasone can be decreased when combined with Dronedarone.Approved
AlfentanilThe metabolism of Alfentanil can be decreased when combined with Dronedarone.Approved, Illicit
AlfuzosinAlfuzosin may increase the antihypertensive activities of Dronedarone.Approved, Investigational
AliskirenThe metabolism of Aliskiren can be decreased when combined with Dronedarone.Approved, Investigational
AllylestrenolThe metabolism of Allylestrenol can be decreased when combined with Dronedarone.Approved
AlmotriptanThe metabolism of Almotriptan can be decreased when combined with Dronedarone.Approved, Investigational
AlogliptinThe metabolism of Alogliptin can be decreased when combined with Dronedarone.Approved
AlosetronThe metabolism of Alosetron can be decreased when combined with Dronedarone.Approved, Withdrawn
alpha-Tocopherol acetateThe metabolism of alpha-Tocopherol acetate can be decreased when combined with Dronedarone.Approved
AlprazolamThe metabolism of Alprazolam can be decreased when combined with Dronedarone.Approved, Illicit, Investigational
AlprenololDronedarone may increase the bradycardic activities of Alprenolol.Approved, Withdrawn
AmantadineAmantadine may increase the QTc-prolonging activities of Dronedarone.Approved
AmbrisentanThe metabolism of Ambrisentan can be decreased when combined with Dronedarone.Approved, Investigational
AmbroxolThe metabolism of Ambroxol can be decreased when combined with Dronedarone.Approved, Investigational
AmibegronDronedarone may decrease the vasoconstricting activities of Amibegron.Investigational
AminophenazoneThe metabolism of Aminophenazone can be decreased when combined with Dronedarone.Approved, Withdrawn
AminophyllineThe metabolism of Aminophylline can be decreased when combined with Dronedarone.Approved
AmiodaroneThe serum concentration of Dronedarone can be increased when it is combined with Amiodarone.Approved, Investigational
AmitrazDronedarone may decrease the vasoconstricting activities of Amitraz.Vet Approved
AmitriptylineDronedarone may increase the antihypertensive activities of Amitriptyline.Approved
AmlodipineThe metabolism of Amlodipine can be decreased when combined with Dronedarone.Approved
AmoxapineDronedarone may increase the antihypertensive activities of Amoxapine.Approved
AmphetamineThe metabolism of Amphetamine can be decreased when combined with Dronedarone.Approved, Illicit, Investigational
AmprenavirThe metabolism of Amprenavir can be decreased when combined with Dronedarone.Approved, Investigational
AmrinoneThe risk or severity of hypotension can be increased when Dronedarone is combined with Amrinone.Approved
AmsacrineThe metabolism of Amsacrine can be decreased when combined with Dronedarone.Approved, Investigational
AnagrelideThe risk or severity of QTc prolongation can be increased when Anagrelide is combined with Dronedarone.Approved
AnisodamineDronedarone may decrease the vasoconstricting activities of Anisodamine.Investigational
AntipyrineThe metabolism of Antipyrine can be decreased when combined with Dronedarone.Approved, Investigational
ApalutamideThe serum concentration of Dronedarone can be decreased when it is combined with Apalutamide.Approved, Investigational
ApixabanThe serum concentration of Apixaban can be increased when it is combined with Dronedarone.Approved
ApomorphineApomorphine may increase the QTc-prolonging activities of Dronedarone.Approved, Investigational
ApraclonidineDronedarone may decrease the vasoconstricting activities of Apraclonidine.Approved
ApremilastThe metabolism of Apremilast can be decreased when combined with Dronedarone.Approved, Investigational
AprepitantThe serum concentration of Dronedarone can be increased when it is combined with Aprepitant.Approved, Investigational
AprindineThe metabolism of Aprindine can be decreased when combined with Dronedarone.Approved
AranidipineThe risk or severity of hypotension can be increased when Dronedarone is combined with Aranidipine.Approved, Investigational
ArbutamineDronedarone may decrease the vasoconstricting activities of Arbutamine.Approved
ArformoterolArformoterol may increase the QTc-prolonging activities of Dronedarone.Approved, Investigational
ArgatrobanThe metabolism of Argatroban can be decreased when combined with Dronedarone.Approved, Investigational
AripiprazoleThe serum concentration of Aripiprazole can be increased when it is combined with Dronedarone.Approved, Investigational
ArotinololDronedarone may increase the bradycardic activities of Arotinolol.Investigational
Arsenic trioxideThe risk or severity of QTc prolongation can be increased when Arsenic trioxide is combined with Dronedarone.Approved, Investigational
ArtemetherThe risk or severity of QTc prolongation can be increased when Dronedarone is combined with Artemether.Approved
AsenapineDronedarone may increase the bradycardic activities of Asenapine.Approved
AstemizoleThe metabolism of Astemizole can be decreased when combined with Dronedarone.Approved, Withdrawn
AsunaprevirThe serum concentration of Asunaprevir can be increased when it is combined with Dronedarone.Approved, Investigational, Withdrawn
AtazanavirThe serum concentration of Dronedarone can be increased when it is combined with Atazanavir.Approved, Investigational
AtenololDronedarone may increase the bradycardic activities of Atenolol.Approved
AtomoxetineAtomoxetine may increase the QTc-prolonging activities of Dronedarone.Approved
AtorvastatinThe risk or severity of adverse effects can be increased when Dronedarone is combined with Atorvastatin.Approved
AvanafilThe serum concentration of Avanafil can be increased when it is combined with Dronedarone.Approved
AvatrombopagThe metabolism of Avatrombopag can be decreased when combined with Dronedarone.Approved, Investigational
AxitinibThe metabolism of Axitinib can be decreased when combined with Dronedarone.Approved, Investigational
AzelastineThe metabolism of Azelastine can be decreased when combined with Dronedarone.Approved
AzelnidipineThe risk or severity of hypotension can be increased when Dronedarone is combined with Azelnidipine.Approved, Investigational
AzimilideThe risk or severity of hypotension can be increased when Dronedarone is combined with Azimilide.Investigational
AzithromycinAzithromycin may increase the QTc-prolonging activities of Dronedarone.Approved
BambuterolDronedarone may decrease the vasoconstricting activities of Bambuterol.Approved, Investigational
BanoxantroneThe metabolism of Banoxantrone can be decreased when combined with Dronedarone.Investigational
BaricitinibThe metabolism of Baricitinib can be decreased when combined with Dronedarone.Approved, Investigational
BarnidipineThe risk or severity of hypotension can be increased when Dronedarone is combined with Barnidipine.Approved
BedaquilineBedaquiline may increase the QTc-prolonging activities of Dronedarone.Approved
BefunololDronedarone may increase the bradycardic activities of Befunolol.Experimental
BencyclaneThe risk or severity of hypotension can be increased when Dronedarone is combined with Bencyclane.Experimental
BendroflumethiazideBendroflumethiazide may increase the bradycardic activities of Dronedarone.Approved
BenidipineThe metabolism of Benidipine can be decreased when combined with Dronedarone.Approved, Investigational
BenzatropineThe metabolism of Benzatropine can be decreased when combined with Dronedarone.Approved
BenzphetamineThe metabolism of Benzphetamine can be decreased when combined with Dronedarone.Approved, Illicit
Benzyl alcoholThe metabolism of Benzyl alcohol can be decreased when combined with Dronedarone.Approved
BepridilThe metabolism of Bepridil can be decreased when combined with Dronedarone.Approved, Withdrawn
BeractantDronedarone may increase the bradycardic activities of Beractant.Approved
BetaxololDronedarone may increase the bradycardic activities of Betaxolol.Approved, Investigational
BevantololDronedarone may increase the bradycardic activities of Bevantolol.Approved
BexaroteneThe metabolism of Bexarotene can be decreased when combined with Dronedarone.Approved, Investigational
BezafibrateThe metabolism of Bezafibrate can be decreased when combined with Dronedarone.Approved, Investigational
BicalutamideThe metabolism of Bicalutamide can be decreased when combined with Dronedarone.Approved
BictegravirThe metabolism of Bictegravir can be decreased when combined with Dronedarone.Approved, Investigational
BioallethrinThe metabolism of Bioallethrin can be decreased when combined with Dronedarone.Approved, Experimental
BisoprololDronedarone may increase the bradycardic activities of Bisoprolol.Approved
BitolterolDronedarone may decrease the vasoconstricting activities of Bitolterol.Withdrawn
BlonanserinThe metabolism of Blonanserin can be decreased when combined with Dronedarone.Approved, Investigational
BoceprevirThe serum concentration of Dronedarone can be increased when it is combined with Boceprevir.Approved, Withdrawn
BopindololDronedarone may increase the bradycardic activities of Bopindolol.Approved
BortezomibBortezomib may increase the QTc-prolonging activities of Dronedarone.Approved, Investigational
BosentanThe serum concentration of Bosentan can be increased when it is combined with Dronedarone.Approved, Investigational
BosutinibThe serum concentration of Bosutinib can be increased when it is combined with Dronedarone.Approved
Brentuximab vedotinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Dronedarone.Approved, Investigational
BretyliumBretylium may increase the bradycardic activities of Dronedarone.Approved
BrexpiprazoleThe serum concentration of Brexpiprazole can be increased when it is combined with Dronedarone.Approved, Investigational
BrigatinibThe serum concentration of Dronedarone can be decreased when it is combined with Brigatinib.Approved, Investigational
BrimonidineDronedarone may decrease the vasoconstricting activities of Brimonidine.Approved
BrinzolamideThe metabolism of Brinzolamide can be decreased when combined with Dronedarone.Approved
BrivaracetamThe metabolism of Brivaracetam can be decreased when combined with Dronedarone.Approved, Investigational
BromazepamThe metabolism of Bromazepam can be decreased when combined with Dronedarone.Approved, Illicit, Investigational
BromocriptineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Dronedarone.Approved, Investigational
BrompheniramineThe metabolism of Brompheniramine can be decreased when combined with Dronedarone.Approved
BucindololDronedarone may increase the bradycardic activities of Bucindolol.Investigational
BudesonideThe serum concentration of Budesonide can be increased when it is combined with Dronedarone.Approved
BufuralolDronedarone may increase the bradycardic activities of Bufuralol.Experimental, Investigational
BunazosinBunazosin may increase the antihypertensive activities of Dronedarone.Investigational
BupivacaineThe metabolism of Bupivacaine can be decreased when combined with Dronedarone.Approved, Investigational
BupranololDronedarone may increase the bradycardic activities of Bupranolol.Approved
BuprenorphineThe metabolism of Buprenorphine can be decreased when combined with Dronedarone.Approved, Illicit, Investigational, Vet Approved
BupropionThe metabolism of Dronedarone can be decreased when combined with Bupropion.Approved
BuserelinBuserelin may increase the QTc-prolonging activities of Dronedarone.Approved, Investigational
BuspironeThe metabolism of Buspirone can be decreased when combined with Dronedarone.Approved, Investigational
BusulfanThe metabolism of Busulfan can be decreased when combined with Dronedarone.Approved, Investigational
CabazitaxelThe metabolism of Cabazitaxel can be decreased when combined with Dronedarone.Approved
CabergolineThe risk or severity of adverse effects can be increased when Cabergoline is combined with Dronedarone.Approved
CabozantinibThe metabolism of Cabozantinib can be decreased when combined with Dronedarone.Approved, Investigational
CaffeineThe metabolism of Caffeine can be decreased when combined with Dronedarone.Approved
CalcitriolThe metabolism of Calcitriol can be decreased when combined with Dronedarone.Approved, Nutraceutical
CalfactantDronedarone may increase the bradycardic activities of Calfactant.Approved
CanagliflozinThe metabolism of Canagliflozin can be decreased when combined with Dronedarone.Approved
CannabidiolThe metabolism of Cannabidiol can be decreased when combined with Dronedarone.Approved, Investigational
CaptoprilThe metabolism of Captopril can be decreased when combined with Dronedarone.Approved
CarbamazepineThe serum concentration of Dronedarone can be decreased when it is combined with Carbamazepine.Approved, Investigational
CarbinoxamineThe metabolism of Carbinoxamine can be decreased when combined with Dronedarone.Approved
CarboxyamidotriazoleThe risk or severity of hypotension can be increased when Dronedarone is combined with Carboxyamidotriazole.Investigational
CariprazineThe metabolism of Cariprazine can be decreased when combined with Dronedarone.Approved, Investigational
CaroverineThe risk or severity of hypotension can be increased when Dronedarone is combined with Caroverine.Experimental
CarteololDronedarone may increase the bradycardic activities of Carteolol.Approved
CarvedilolDronedarone may increase the bradycardic activities of Carvedilol.Approved, Investigational
CelecoxibThe metabolism of Celecoxib can be decreased when combined with Dronedarone.Approved, Investigational
CeliprololDronedarone may increase the bradycardic activities of Celiprolol.Approved, Investigational
CephalexinThe metabolism of Cephalexin can be decreased when combined with Dronedarone.Approved, Investigational, Vet Approved
CeritinibDronedarone may increase the bradycardic activities of Ceritinib.Approved
CerivastatinThe serum concentration of Cerivastatin can be increased when it is combined with Dronedarone.Approved, Withdrawn
CevimelineThe metabolism of Cevimeline can be decreased when combined with Dronedarone.Approved
Chenodeoxycholic acidThe metabolism of Chenodeoxycholic acid can be decreased when combined with Dronedarone.Approved
ChlordiazepoxideThe metabolism of Chlordiazepoxide can be decreased when combined with Dronedarone.Approved, Illicit, Investigational
ChloroquineChloroquine may increase the QTc-prolonging activities of Dronedarone.Approved, Investigational, Vet Approved
ChlorphenamineThe metabolism of Chlorphenamine can be decreased when combined with Dronedarone.Approved
ChlorpromazineChlorpromazine may increase the QTc-prolonging activities of Dronedarone.Approved, Investigational, Vet Approved
ChlorzoxazoneThe metabolism of Chlorzoxazone can be decreased when combined with Dronedarone.Approved
CholecalciferolThe metabolism of Cholecalciferol can be decreased when combined with Dronedarone.Approved, Nutraceutical
CiclesonideThe metabolism of Ciclesonide can be decreased when combined with Dronedarone.Approved, Investigational
CilnidipineThe risk or severity of hypotension can be increased when Dronedarone is combined with Cilnidipine.Approved, Investigational
CilostazolThe serum concentration of Cilostazol can be increased when it is combined with Dronedarone.Approved, Investigational
CimetidineThe metabolism of Dronedarone can be decreased when combined with Cimetidine.Approved, Investigational
CinacalcetThe metabolism of Dronedarone can be decreased when combined with Cinacalcet.Approved
CinnarizineThe metabolism of Cinnarizine can be decreased when combined with Dronedarone.Approved, Investigational
CiprofloxacinCiprofloxacin may increase the QTc-prolonging activities of Dronedarone.Approved, Investigational
CirazolineDronedarone may decrease the vasoconstricting activities of Cirazoline.Experimental
CisaprideThe risk or severity of QTc prolongation can be increased when Cisapride is combined with Dronedarone.Approved, Investigational, Withdrawn
CitalopramThe risk or severity of QTc prolongation can be increased when Citalopram is combined with Dronedarone.Approved
ClarithromycinThe serum concentration of Dronedarone can be increased when it is combined with Clarithromycin.Approved
ClemastineThe metabolism of Dronedarone can be decreased when combined with Clemastine.Approved, Investigational
ClenbuterolDronedarone may decrease the vasoconstricting activities of Clenbuterol.Approved, Investigational, Vet Approved
ClevidipineThe metabolism of Clevidipine can be decreased when combined with Dronedarone.Approved, Investigational
ClindamycinThe metabolism of Clindamycin can be decreased when combined with Dronedarone.Approved, Vet Approved
ClobazamThe metabolism of Clobazam can be decreased when combined with Dronedarone.Approved, Illicit
ClofazimineThe metabolism of Clofazimine can be decreased when combined with Dronedarone.Approved, Investigational
ClofibrateThe metabolism of Clofibrate can be decreased when combined with Dronedarone.Approved, Investigational
clomethiazoleThe metabolism of clomethiazole can be decreased when combined with Dronedarone.Investigational
ClomipramineClomipramine may increase the QTc-prolonging activities of Dronedarone.Approved, Investigational, Vet Approved
ClonazepamThe metabolism of Clonazepam can be decreased when combined with Dronedarone.Approved, Illicit
ClonidineThe metabolism of Clonidine can be decreased when combined with Dronedarone.Approved
ClopidogrelThe metabolism of Clopidogrel can be decreased when combined with Dronedarone.Approved
CloranololDronedarone may increase the bradycardic activities of Cloranolol.Experimental
ClorazepateThe metabolism of Clorazepate can be decreased when combined with Dronedarone.Approved, Illicit
ClorindioneThe serum concentration of Clorindione can be increased when it is combined with Dronedarone.Experimental
ClotiazepamThe metabolism of Clotiazepam can be decreased when combined with Dronedarone.Approved, Illicit
ClotrimazoleThe metabolism of Dronedarone can be decreased when combined with Clotrimazole.Approved, Vet Approved
ClozapineClozapine may increase the QTc-prolonging activities of Dronedarone.Approved
CobicistatThe serum concentration of Dronedarone can be increased when it is combined with Cobicistat.Approved
CobimetinibThe serum concentration of Cobimetinib can be increased when it is combined with Dronedarone.Approved, Investigational
CocaineThe metabolism of Dronedarone can be decreased when combined with Cocaine.Approved, Illicit
CodeineThe therapeutic efficacy of Codeine can be decreased when used in combination with Dronedarone.Approved, Illicit
ColchicineThe serum concentration of Colchicine can be increased when it is combined with Dronedarone.Approved
ConivaptanThe serum concentration of Conivaptan can be increased when it is combined with Dronedarone.Approved, Investigational
Conjugated estrogensThe metabolism of Conjugated estrogens can be decreased when combined with Dronedarone.Approved
CopanlisibThe metabolism of Copanlisib can be decreased when combined with Dronedarone.Approved, Investigational
Cortisone acetateThe metabolism of Cortisone acetate can be decreased when combined with Dronedarone.Approved, Investigational
CrizotinibCrizotinib may increase the QTc-prolonging activities of Dronedarone.Approved
CurcuminThe serum concentration of Dronedarone can be increased when it is combined with Curcumin.Approved, Investigational
CyclandelateThe risk or severity of hypotension can be increased when Dronedarone is combined with Cyclandelate.Approved
CyclobenzaprineThe metabolism of Cyclobenzaprine can be decreased when combined with Dronedarone.Approved
CyclophosphamideThe metabolism of Cyclophosphamide can be decreased when combined with Dronedarone.Approved, Investigational
CyclosporineThe serum concentration of Dronedarone can be increased when it is combined with Cyclosporine.Approved, Investigational, Vet Approved
CytarabineThe metabolism of Cytarabine can be decreased when combined with Dronedarone.Approved, Investigational
Dabigatran etexilateThe serum concentration of Dabigatran etexilate can be increased when it is combined with Dronedarone.Approved
DabrafenibThe serum concentration of Dronedarone can be decreased when it is combined with Dabrafenib.Approved, Investigational
DaclatasvirThe metabolism of Daclatasvir can be decreased when combined with Dronedarone.Approved, Investigational
DantroleneThe metabolism of Dantrolene can be decreased when combined with Dronedarone.Approved, Investigational
DapagliflozinThe metabolism of Dapagliflozin can be decreased when combined with Dronedarone.Approved
DapiprazoleDapiprazole may increase the antihypertensive activities of Dronedarone.Approved
DapoxetineThe serum concentration of Dapoxetine can be increased when it is combined with Dronedarone.Investigational
DapsoneThe metabolism of Dapsone can be decreased when combined with Dronedarone.Approved, Investigational
DarifenacinThe metabolism of Darifenacin can be decreased when combined with Dronedarone.Approved, Investigational
DarodipineThe risk or severity of hypotension can be increased when Dronedarone is combined with Darodipine.Experimental
DarunavirThe serum concentration of Dronedarone can be increased when it is combined with Darunavir.Approved
DasabuvirThe metabolism of Dasabuvir can be decreased when combined with Dronedarone.Approved
DasatinibThe serum concentration of Dronedarone can be increased when it is combined with Dasatinib.Approved, Investigational
DaunorubicinThe metabolism of Daunorubicin can be decreased when combined with Dronedarone.Approved
DebrisoquinThe metabolism of Debrisoquin can be decreased when combined with Dronedarone.Approved, Investigational
DeferasiroxThe serum concentration of Dronedarone can be decreased when it is combined with Deferasirox.Approved, Investigational
DeflazacortThe metabolism of Deflazacort can be decreased when combined with Dronedarone.Approved, Investigational
DegarelixDegarelix may increase the QTc-prolonging activities of Dronedarone.Approved
DelamanidDronedarone may increase the QTc-prolonging activities of Delamanid.Approved, Investigational
DelavirdineThe metabolism of Dronedarone can be decreased when combined with Delavirdine.Approved
DesfluraneDesflurane may increase the QTc-prolonging activities of Dronedarone.Approved
DesipramineDronedarone may increase the bradycardic activities of Desipramine.Approved, Investigational
DesvenlafaxineThe metabolism of Desvenlafaxine can be decreased when combined with Dronedarone.Approved, Investigational
DetomidineDronedarone may decrease the vasoconstricting activities of Detomidine.Vet Approved
DeutetrabenazineDronedarone may increase the QTc-prolonging activities of Deutetrabenazine.Approved, Investigational
DexamethasoneThe metabolism of Dexamethasone can be decreased when combined with Dronedarone.Approved, Investigational, Vet Approved
Dexchlorpheniramine maleateThe metabolism of Dexchlorpheniramine maleate can be decreased when combined with Dronedarone.Approved
DexfenfluramineThe metabolism of Dexfenfluramine can be decreased when combined with Dronedarone.Approved, Illicit, Investigational, Withdrawn
DexlansoprazoleThe metabolism of Dexlansoprazole can be decreased when combined with Dronedarone.Approved, Investigational
DexmedetomidineDexmedetomidine may increase the bradycardic activities of Dronedarone.Approved, Vet Approved
DexmethylphenidateThe metabolism of Dexmethylphenidate can be decreased when combined with Dronedarone.Approved, Investigational
DextroamphetamineDronedarone may increase the antihypertensive activities of Dextroamphetamine.Approved, Illicit
DextromethorphanThe metabolism of Dextromethorphan can be decreased when combined with Dronedarone.Approved
DextropropoxypheneThe metabolism of Dextropropoxyphene can be decreased when combined with Dronedarone.Approved, Illicit, Investigational, Withdrawn
DiazepamThe metabolism of Diazepam can be decreased when combined with Dronedarone.Approved, Illicit, Investigational, Vet Approved
DiclofenacThe metabolism of Diclofenac can be decreased when combined with Dronedarone.Approved, Vet Approved
DicoumarolThe serum concentration of Dicoumarol can be increased when it is combined with Dronedarone.Approved
DienogestThe metabolism of Dienogest can be decreased when combined with Dronedarone.Approved
DigitoxinThe metabolism of Digitoxin can be decreased when combined with Dronedarone.Approved, Investigational
DigoxinDigoxin may increase the atrioventricular blocking (AV block) activities of Dronedarone.Approved
Dihydro-alpha-ergocryptineThe metabolism of Dihydro-alpha-ergocryptine can be decreased when combined with Dronedarone.Approved
DihydrocodeineThe metabolism of Dihydrocodeine can be decreased when combined with Dronedarone.Approved, Illicit
DihydroergocornineThe risk or severity of adverse effects can be increased when Dihydroergocornine is combined with Dronedarone.Approved
DihydroergocristineThe risk or severity of adverse effects can be increased when Dihydroergocristine is combined with Dronedarone.Approved, Experimental
DihydroergocryptineThe risk or severity of adverse effects can be increased when Dihydroergocryptine is combined with Dronedarone.Experimental
DihydroergotamineThe risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Dronedarone.Approved, Investigational
DiltiazemDiltiazem may increase the atrioventricular blocking (AV block) activities of Dronedarone.Approved, Investigational
DiphenadioneThe serum concentration of Diphenadione can be increased when it is combined with Dronedarone.Experimental
DiphenhydramineDiphenhydramine may increase the QTc-prolonging activities of Dronedarone.Approved, Investigational
DipivefrinDronedarone may decrease the vasoconstricting activities of Dipivefrin.Approved
DipyridamoleDipyridamole may increase the hypotensive activities of Dronedarone.Approved
DisopyramideThe risk or severity of QTc prolongation can be increased when Disopyramide is combined with Dronedarone.Approved
DisulfiramThe metabolism of Disulfiram can be decreased when combined with Dronedarone.Approved
DL-MethylephedrineDronedarone may decrease the vasoconstricting activities of DL-Methylephedrine.Approved
DobutamineDronedarone may decrease the vasoconstricting activities of Dobutamine.Approved
DocetaxelThe serum concentration of Docetaxel can be increased when it is combined with Dronedarone.Approved, Investigational
DofetilideThe serum concentration of Dofetilide can be increased when it is combined with Dronedarone.Approved, Investigational
DolasetronDolasetron may increase the QTc-prolonging activities of Dronedarone.Approved, Investigational
DomperidoneThe serum concentration of Domperidone can be increased when it is combined with Dronedarone.Approved, Investigational, Vet Approved
DonepezilThe metabolism of Donepezil can be decreased when combined with Dronedarone.Approved
DopamineThe metabolism of Dopamine can be decreased when combined with Dronedarone.Approved
DopexamineDronedarone may decrease the vasoconstricting activities of Dopexamine.Approved, Investigational
DorzolamideThe metabolism of Dorzolamide can be decreased when combined with Dronedarone.Approved
DosulepinThe metabolism of Dronedarone can be decreased when combined with Dosulepin.Approved
DotarizineThe risk or severity of hypotension can be increased when Dronedarone is combined with Dotarizine.Investigational
DoxazosinDoxazosin may increase the antihypertensive activities of Dronedarone.Approved
DoxepinDronedarone may increase the antihypertensive activities of Doxepin.Approved, Investigational
DoxofyllineDronedarone may decrease the vasoconstricting activities of Doxofylline.Approved, Investigational
DoxorubicinThe serum concentration of Doxorubicin can be increased when it is combined with Dronedarone.Approved, Investigational
DoxorubicinThe metabolism of Doxorubicin can be decreased when combined with Dronedarone.Approved, Investigational
DoxycyclineThe metabolism of Dronedarone can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DronabinolThe serum concentration of Dronabinol can be increased when it is combined with Dronedarone.Approved, Illicit
DroperidolDroperidol may increase the QTc-prolonging activities of Dronedarone.Approved, Vet Approved
DroxidopaDronedarone may decrease the vasoconstricting activities of Droxidopa.Approved, Investigational
DuloxetineThe metabolism of Dronedarone can be decreased when combined with Duloxetine.Approved
DutasterideThe metabolism of Dutasteride can be decreased when combined with Dronedarone.Approved, Investigational
EdoxabanThe serum concentration of Edoxaban can be increased when it is combined with Dronedarone.Approved
EfavirenzThe metabolism of Efavirenz can be decreased when combined with Dronedarone.Approved, Investigational
EfonidipineThe risk or severity of hypotension can be increased when Dronedarone is combined with Efonidipine.Approved, Investigational
ElbasvirThe metabolism of Elbasvir can be decreased when combined with Dronedarone.Approved
EletriptanThe serum concentration of Eletriptan can be increased when it is combined with Dronedarone.Approved, Investigational
EliglustatThe serum concentration of Eliglustat can be increased when it is combined with Dronedarone.Approved
ElvitegravirThe metabolism of Elvitegravir can be decreased when combined with Dronedarone.Approved
EnalaprilThe metabolism of Enalapril can be decreased when combined with Dronedarone.Approved, Vet Approved
EnasidenibThe metabolism of Enasidenib can be decreased when combined with Dronedarone.Approved, Investigational
EncainideThe metabolism of Encainide can be decreased when combined with Dronedarone.Approved, Investigational, Withdrawn
EnclomipheneThe metabolism of Enclomiphene can be decreased when combined with Dronedarone.Investigational
EnzalutamideThe serum concentration of Dronedarone can be decreased when it is combined with Enzalutamide.Approved
EpanololDronedarone may increase the bradycardic activities of Epanolol.Experimental
EperisoneThe risk or severity of hypotension can be increased when Dronedarone is combined with Eperisone.Approved, Investigational
EphedraDronedarone may decrease the vasoconstricting activities of Ephedra.Approved, Nutraceutical, Withdrawn
EphedrineDronedarone may decrease the vasoconstricting activities of Ephedrine.Approved
EpinastineThe metabolism of Epinastine can be decreased when combined with Dronedarone.Approved, Investigational
EpinephrineDronedarone may increase the antihypertensive activities of Epinephrine.Approved, Vet Approved
EplerenoneThe serum concentration of Eplerenone can be increased when it is combined with Dronedarone.Approved
ErgocalciferolThe metabolism of Ergocalciferol can be decreased when combined with Dronedarone.Approved, Nutraceutical
Ergoloid mesylateThe metabolism of Ergoloid mesylate can be decreased when combined with Dronedarone.Approved
ErgonovineThe risk or severity of adverse effects can be increased when Ergonovine is combined with Dronedarone.Approved
ErgotamineThe risk or severity of adverse effects can be increased when Ergotamine is combined with Dronedarone.Approved
EribulinEribulin may increase the QTc-prolonging activities of Dronedarone.Approved, Investigational
ErlotinibThe metabolism of Erlotinib can be decreased when combined with Dronedarone.Approved, Investigational
ErythromycinErythromycin may increase the QTc-prolonging activities of Dronedarone.Approved, Investigational, Vet Approved
EsatenololDronedarone may increase the bradycardic activities of Esatenolol.Experimental
EscitalopramThe risk or severity of QTc prolongation can be increased when Escitalopram is combined with Dronedarone.Approved, Investigational
EsmirtazapineThe metabolism of Esmirtazapine can be decreased when combined with Dronedarone.Investigational
EsmololDronedarone may increase the bradycardic activities of Esmolol.Approved
EsomeprazoleThe metabolism of Esomeprazole can be decreased when combined with Dronedarone.Approved, Investigational
EstazolamThe metabolism of Estazolam can be decreased when combined with Dronedarone.Approved, Illicit
EstradiolThe metabolism of Estradiol can be decreased when combined with Dronedarone.Approved, Investigational, Vet Approved
Estradiol acetateThe metabolism of Estradiol acetate can be decreased when combined with Dronedarone.Approved, Investigational, Vet Approved
Estradiol benzoateThe metabolism of Estradiol benzoate can be decreased when combined with Dronedarone.Approved, Investigational, Vet Approved
Estradiol cypionateThe metabolism of Estradiol cypionate can be decreased when combined with Dronedarone.Approved, Investigational, Vet Approved
Estradiol dienanthateThe metabolism of Estradiol dienanthate can be decreased when combined with Dronedarone.Approved, Investigational, Vet Approved
Estradiol valerateThe metabolism of Estradiol valerate can be decreased when combined with Dronedarone.Approved, Investigational, Vet Approved
EstramustineThe metabolism of Estramustine can be decreased when combined with Dronedarone.Approved, Investigational
Estrogens, esterifiedThe metabolism of Estrogens, esterified can be decreased when combined with Dronedarone.Approved
EstroneThe metabolism of Estrone can be decreased when combined with Dronedarone.Approved
Estrone sulfateThe metabolism of Estrone sulfate can be decreased when combined with Dronedarone.Approved
EszopicloneThe metabolism of Eszopiclone can be decreased when combined with Dronedarone.Approved, Investigational
EtafedrineDronedarone may decrease the vasoconstricting activities of Etafedrine.Approved
EthanolThe metabolism of Ethanol can be decreased when combined with Dronedarone.Approved
Ethinyl EstradiolThe metabolism of Ethinyl Estradiol can be decreased when combined with Dronedarone.Approved
EthosuximideThe metabolism of Ethosuximide can be decreased when combined with Dronedarone.Approved
Ethyl biscoumacetateThe serum concentration of Ethyl biscoumacetate can be increased when it is combined with Dronedarone.Withdrawn
EthylmorphineThe metabolism of Ethylmorphine can be decreased when combined with Dronedarone.Approved, Illicit
EtilefrineDronedarone may decrease the vasoconstricting activities of Etilefrine.Withdrawn
EtizolamThe metabolism of Etizolam can be decreased when combined with Dronedarone.Approved
EtomidateDronedarone may decrease the vasoconstricting activities of Etomidate.Approved
EtonogestrelThe metabolism of Etonogestrel can be decreased when combined with Dronedarone.Approved, Investigational
EtoposideThe metabolism of Etoposide can be decreased when combined with Dronedarone.Approved
EtoricoxibThe metabolism of Etoricoxib can be decreased when combined with Dronedarone.Approved, Investigational
EtravirineThe metabolism of Etravirine can be decreased when combined with Dronedarone.Approved
EverolimusThe serum concentration of Everolimus can be increased when it is combined with Dronedarone.Approved
ExemestaneThe metabolism of Exemestane can be decreased when combined with Dronedarone.Approved, Investigational
EzogabineEzogabine may increase the QTc-prolonging activities of Dronedarone.Approved, Investigational
FamciclovirThe metabolism of Famciclovir can be decreased when combined with Dronedarone.Approved, Investigational
FamotidineFamotidine may increase the QTc-prolonging activities of Dronedarone.Approved
FelbamateFelbamate may increase the QTc-prolonging activities of Dronedarone.Approved
FelodipineThe metabolism of Felodipine can be decreased when combined with Dronedarone.Approved, Investigational
FendilineThe risk or severity of hypotension can be increased when Dronedarone is combined with Fendiline.Withdrawn
FenofibrateThe metabolism of Fenofibrate can be decreased when combined with Dronedarone.Approved
FenoterolDronedarone may decrease the vasoconstricting activities of Fenoterol.Approved, Investigational
FentanylThe serum concentration of Fentanyl can be increased when it is combined with Dronedarone.Approved, Illicit, Investigational, Vet Approved
FesoterodineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Dronedarone.Approved
FinasterideThe metabolism of Finasteride can be decreased when combined with Dronedarone.Approved
FingolimodFingolimod may increase the arrhythmogenic activities of Dronedarone.Approved, Investigational
Fish oilThe risk or severity of hypotension can be increased when Dronedarone is combined with Fish oil.Approved, Nutraceutical
FlecainideFlecainide may increase the QTc-prolonging activities of Dronedarone.Approved, Withdrawn
FlibanserinThe risk or severity of adverse effects can be increased when Dronedarone is combined with Flibanserin.Approved, Investigational
FluconazoleFluconazole may increase the QTc-prolonging activities of Dronedarone.Approved, Investigational
FluindioneThe serum concentration of Fluindione can be increased when it is combined with Dronedarone.Approved, Investigational
FlunarizineThe metabolism of Flunarizine can be decreased when combined with Dronedarone.Approved
FlunisolideThe metabolism of Flunisolide can be decreased when combined with Dronedarone.Approved, Investigational
FlunitrazepamThe metabolism of Flunitrazepam can be decreased when combined with Dronedarone.Approved, Illicit
FluorometholoneThe metabolism of Fluorometholone can be decreased when combined with Dronedarone.Approved, Investigational
FluoxetineThe risk or severity of QTc prolongation can be increased when Fluoxetine is combined with Dronedarone.Approved, Vet Approved
FlupentixolThe risk or severity of QTc prolongation can be increased when Flupentixol is combined with Dronedarone.Approved, Investigational, Withdrawn
FluphenazineThe metabolism of Fluphenazine can be decreased when combined with Dronedarone.Approved
FlurazepamThe metabolism of Flurazepam can be decreased when combined with Dronedarone.Approved, Illicit, Investigational
FluspirileneThe risk or severity of hypotension can be increased when Dronedarone is combined with Fluspirilene.Approved, Investigational
FlutamideThe metabolism of Flutamide can be decreased when combined with Dronedarone.Approved, Investigational
Fluticasone furoateThe metabolism of Fluticasone furoate can be decreased when combined with Dronedarone.Approved
Fluticasone propionateThe metabolism of Fluticasone propionate can be decreased when combined with Dronedarone.Approved
FluvastatinThe serum concentration of Fluvastatin can be increased when it is combined with Dronedarone.Approved
FluvoxamineThe metabolism of Dronedarone can be decreased when combined with Fluvoxamine.Approved, Investigational
FormoterolFormoterol may increase the QTc-prolonging activities of Dronedarone.Approved, Investigational
FosamprenavirThe metabolism of Dronedarone can be decreased when combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Dronedarone can be increased when it is combined with Fosaprepitant.Approved
FoscarnetFoscarnet may increase the QTc-prolonging activities of Dronedarone.Approved
FosnetupitantThe metabolism of Fosnetupitant can be decreased when combined with Dronedarone.Approved
FosphenytoinThe serum concentration of Dronedarone can be decreased when it is combined with Fosphenytoin.Approved, Investigational
FostamatinibFostamatinib may increase the hypotensive activities of Dronedarone.Approved, Investigational
FulvestrantThe metabolism of Fulvestrant can be decreased when combined with Dronedarone.Approved, Investigational
Fusidic AcidThe serum concentration of Dronedarone can be increased when it is combined with Fusidic Acid.Approved, Investigational
GabapentinThe risk or severity of hypotension can be increased when Dronedarone is combined with Gabapentin.Approved, Investigational
Gadobenic acidGadobenic acid may increase the QTc-prolonging activities of Dronedarone.Approved, Investigational
GalantamineGalantamine may increase the QTc-prolonging activities of Dronedarone.Approved
GallopamilThe risk or severity of hypotension can be increased when Dronedarone is combined with Gallopamil.Investigational
GefitinibThe metabolism of Gefitinib can be decreased when combined with Dronedarone.Approved, Investigational
GemfibrozilThe metabolism of Gemfibrozil can be decreased when combined with Dronedarone.Approved
GemifloxacinGemifloxacin may increase the QTc-prolonging activities of Dronedarone.Approved, Investigational
GlipizideThe metabolism of Glipizide can be decreased when combined with Dronedarone.Approved, Investigational
GlyburideThe metabolism of Glyburide can be decreased when combined with Dronedarone.Approved
GoserelinGoserelin may increase the QTc-prolonging activities of Dronedarone.Approved
GranisetronGranisetron may increase the QTc-prolonging activities of Dronedarone.Approved, Investigational
GrazoprevirThe metabolism of Grazoprevir can be decreased when combined with Dronedarone.Approved
GrepafloxacinThe metabolism of Grepafloxacin can be decreased when combined with Dronedarone.Approved, Investigational, Withdrawn
GuanabenzDronedarone may decrease the vasoconstricting activities of Guanabenz.Approved, Investigational
GuanfacineThe metabolism of Guanfacine can be decreased when combined with Dronedarone.Approved, Investigational
HalofantrineThe serum concentration of Halofantrine can be increased when it is combined with Dronedarone.Approved
HaloperidolHaloperidol may increase the QTc-prolonging activities of Dronedarone.Approved
HalothaneThe metabolism of Halothane can be decreased when combined with Dronedarone.Approved, Vet Approved
HexobarbitalThe metabolism of Hexobarbital can be decreased when combined with Dronedarone.Approved
HexoprenalineDronedarone may decrease the vasoconstricting activities of Hexoprenaline.Approved, Withdrawn
HigenamineDronedarone may decrease the vasoconstricting activities of Higenamine.Investigational
HistamineThe metabolism of Histamine can be decreased when combined with Dronedarone.Approved, Investigational
HistrelinHistrelin may increase the QTc-prolonging activities of Dronedarone.Approved
HydrocodoneThe serum concentration of Hydrocodone can be increased when it is combined with Dronedarone.Approved, Illicit
HydrocortisoneThe metabolism of Hydrocortisone can be decreased when combined with Dronedarone.Approved, Vet Approved
HydromorphoneThe metabolism of Hydromorphone can be decreased when combined with Dronedarone.Approved, Illicit
Hydroxyprogesterone caproateThe metabolism of Hydroxyprogesterone caproate can be decreased when combined with Dronedarone.Approved, Investigational
HydroxyzineHydroxyzine may increase the QTc-prolonging activities of Dronedarone.Approved
IbandronateIbandronate may increase the QTc-prolonging activities of Dronedarone.Approved, Investigational
IbrutinibThe serum concentration of Ibrutinib can be increased when it is combined with Dronedarone.Approved
IbutilideThe risk or severity of QTc prolongation can be increased when Ibutilide is combined with Dronedarone.Approved
IcotinibThe metabolism of Icotinib can be decreased when combined with Dronedarone.Approved, Investigational
IdarubicinThe metabolism of Idarubicin can be decreased when combined with Dronedarone.Approved
IdelalisibThe serum concentration of Dronedarone can be increased when it is combined with Idelalisib.Approved
IfosfamideThe serum concentration of the active metabolites of Ifosfamide can be reduced when Ifosfamide is used in combination with Dronedarone resulting in a loss in efficacy.Approved
IloperidoneThe risk or severity of QTc prolongation can be increased when Dronedarone is combined with Iloperidone.Approved
ImatinibThe serum concentration of Imatinib can be increased when it is combined with Dronedarone.Approved
ImidafenacinThe metabolism of Imidafenacin can be decreased when combined with Dronedarone.Approved, Investigational
ImipramineDronedarone may increase the antihypertensive activities of Imipramine.Approved
ImiquimodThe metabolism of Imiquimod can be decreased when combined with Dronedarone.Approved, Investigational
IndacaterolIndacaterol may increase the QTc-prolonging activities of Dronedarone.Approved
IndapamideIndapamide may increase the QTc-prolonging activities of Dronedarone.Approved
IndenololDronedarone may increase the bradycardic activities of Indenolol.Withdrawn
IndinavirThe serum concentration of Dronedarone can be increased when it is combined with Indinavir.Approved
IndoraminIndoramin may increase the antihypertensive activities of Dronedarone.Withdrawn
IpecacThe metabolism of Ipecac can be decreased when combined with Dronedarone.Approved, Withdrawn
IpratropiumThe metabolism of Ipratropium bromide can be decreased when combined with Dronedarone.Approved
IrinotecanThe metabolism of Irinotecan can be decreased when combined with Dronedarone.Approved, Investigational
IsavuconazoleThe serum concentration of Dronedarone can be increased when it is combined with Isavuconazole.Approved, Investigational
IsavuconazoniumThe metabolism of Isavuconazonium can be decreased when combined with Dronedarone.Approved, Investigational
IsoetarineDronedarone may decrease the vasoconstricting activities of Isoetarine.Approved
IsofluraneIsoflurane may increase the QTc-prolonging activities of Dronedarone.Approved, Vet Approved
IsomethepteneDronedarone may decrease the vasoconstricting activities of Isometheptene.Approved
IsoniazidThe metabolism of Dronedarone can be decreased when combined with Isoniazid.Approved, Investigational
IsoprenalineDronedarone may decrease the vasoconstricting activities of Isoprenaline.Approved, Investigational
Isosorbide DinitrateThe metabolism of Isosorbide Dinitrate can be decreased when combined with Dronedarone.Approved, Investigational
Isosorbide MononitrateThe metabolism of Isosorbide Mononitrate can be decreased when combined with Dronedarone.Approved
IsoxsuprineDronedarone may decrease the vasoconstricting activities of Isoxsuprine.Approved, Withdrawn
IsradipineIsradipine may increase the QTc-prolonging activities of Dronedarone.Approved, Investigational
ItraconazoleThe serum concentration of Dronedarone can be increased when it is combined with Itraconazole.Approved, Investigational
IvabradineThe serum concentration of Ivabradine can be increased when it is combined with Dronedarone.Approved
IvacaftorThe serum concentration of Ivacaftor can be increased when it is combined with Dronedarone.Approved
IvermectinThe metabolism of Ivermectin can be decreased when combined with Dronedarone.Approved, Investigational, Vet Approved
IxabepiloneThe metabolism of Ixabepilone can be decreased when combined with Dronedarone.Approved, Investigational
IxazomibThe metabolism of Ixazomib can be decreased when combined with Dronedarone.Approved, Investigational
KetamineThe metabolism of Ketamine can be decreased when combined with Dronedarone.Approved, Vet Approved
KetazolamThe metabolism of Ketazolam can be decreased when combined with Dronedarone.Approved
KetobemidoneThe metabolism of Ketobemidone can be decreased when combined with Dronedarone.Approved, Investigational
KetoconazoleThe serum concentration of Dronedarone can be increased when it is combined with Ketoconazole.Approved, Investigational
LabetalolDronedarone may increase the bradycardic activities of Labetalol.Approved
LacidipineThe metabolism of Lacidipine can be decreased when combined with Dronedarone.Approved, Investigational
LacosamideDronedarone may increase the atrioventricular blocking (AV block) activities of Lacosamide.Approved
LamotrigineThe risk or severity of hypotension can be increased when Dronedarone is combined with Lamotrigine.Approved, Investigational
LandiololDronedarone may increase the bradycardic activities of Landiolol.Investigational
LanreotideDronedarone may increase the bradycardic activities of Lanreotide.Approved
LansoprazoleThe metabolism of Lansoprazole can be decreased when combined with Dronedarone.Approved, Investigational
LapatinibLapatinib may increase the QTc-prolonging activities of Dronedarone.Approved, Investigational
LaquinimodThe metabolism of Laquinimod can be decreased when combined with Dronedarone.Investigational
LedipasvirThe serum concentration of Ledipasvir can be increased when it is combined with Dronedarone.Approved
LenvatinibLenvatinib may increase the QTc-prolonging activities of Dronedarone.Approved, Investigational
LercanidipineThe metabolism of Lercanidipine can be decreased when combined with Dronedarone.Approved, Investigational
LetermovirThe metabolism of Letermovir can be decreased when combined with Dronedarone.Approved, Investigational
LetrozoleThe metabolism of Letrozole can be decreased when combined with Dronedarone.Approved, Investigational
LeuprolideLeuprolide may increase the QTc-prolonging activities of Dronedarone.Approved, Investigational
LevetiracetamThe risk or severity of hypotension can be increased when Dronedarone is combined with Levetiracetam.Approved, Investigational
LevobetaxololDronedarone may increase the bradycardic activities of Levobetaxolol.Approved, Investigational
LevobunololDronedarone may increase the bradycardic activities of Levobunolol.Approved
LevobupivacaineThe metabolism of Levobupivacaine can be decreased when combined with Dronedarone.Approved, Investigational
LevocetirizineThe metabolism of Levocetirizine can be decreased when combined with Dronedarone.Approved
LevodopaThe metabolism of Levodopa can be decreased when combined with Dronedarone.Approved
LevofloxacinLevofloxacin may increase the QTc-prolonging activities of Dronedarone.Approved, Investigational
Levomethadyl AcetateThe metabolism of Levomethadyl Acetate can be decreased when combined with Dronedarone.Approved, Investigational
LevomilnacipranThe metabolism of Levomilnacipran can be decreased when combined with Dronedarone.Approved, Investigational
LevonorgestrelThe metabolism of Levonorgestrel can be decreased when combined with Dronedarone.Approved, Investigational
LevosalbutamolDronedarone may decrease the vasoconstricting activities of Levosalbutamol.Approved, Investigational
LevothyroxineThe metabolism of Levothyroxine can be decreased when combined with Dronedarone.Approved
LidocaineLidocaine may increase the arrhythmogenic activities of Dronedarone.Approved, Vet Approved
LidoflazineThe risk or severity of hypotension can be increased when Dronedarone is combined with Lidoflazine.Experimental
LisdexamfetamineDronedarone may increase the antihypertensive activities of Lisdexamfetamine.Approved, Investigational
LisurideThe risk or severity of adverse effects can be increased when Lisuride is combined with Dronedarone.Approved, Investigational
Lithium cationLithium may increase the QTc-prolonging activities of Dronedarone.Experimental
LofexidineThe metabolism of Lofexidine can be decreased when combined with Dronedarone.Approved, Investigational
LomitapideThe serum concentration of Lomitapide can be increased when it is combined with Dronedarone.Approved, Investigational
LomustineThe metabolism of Lomustine can be decreased when combined with Dronedarone.Approved, Investigational
LoperamideThe metabolism of Loperamide can be decreased when combined with Dronedarone.Approved
LopinavirThe serum concentration of Dronedarone can be increased when it is combined with Lopinavir.Approved
LoratadineThe metabolism of Loratadine can be decreased when combined with Dronedarone.Approved, Investigational
LorcaserinThe metabolism of Lorcaserin can be decreased when combined with Dronedarone.Approved
LorpiprazoleThe serum concentration of Dronedarone can be increased when it is combined with Lorpiprazole.Approved
LosartanThe metabolism of Losartan can be decreased when combined with Dronedarone.Approved
LovastatinThe serum concentration of Lovastatin can be increased when it is combined with Dronedarone.Approved, Investigational
LucinactantDronedarone may increase the bradycardic activities of Lucinactant.Approved, Investigational
LuliconazoleThe serum concentration of Dronedarone can be increased when it is combined with Luliconazole.Approved
LumacaftorThe serum concentration of Dronedarone can be decreased when it is combined with Lumacaftor.Approved
LumefantrineThe risk or severity of QTc prolongation can be increased when Dronedarone is combined with Lumefantrine.Approved
LurasidoneThe serum concentration of Lurasidone can be increased when it is combined with Dronedarone.Approved, Investigational
Lysergic Acid DiethylamideThe risk or severity of adverse effects can be increased when Lysergic Acid Diethylamide is combined with Dronedarone.Illicit, Investigational, Withdrawn
MacimorelinDronedarone may increase the QTc-prolonging activities of Macimorelin.Approved, Investigational
MacitentanThe metabolism of Macitentan can be decreased when combined with Dronedarone.Approved
Magnesium sulfateThe risk or severity of hypotension can be increased when Dronedarone is combined with Magnesium sulfate.Approved, Investigational, Vet Approved
ManidipineThe metabolism of Dronedarone can be decreased when combined with Manidipine.Approved, Investigational
MaprotilineMaprotiline may increase the QTc-prolonging activities of Dronedarone.Approved, Investigational
MaravirocThe metabolism of Maraviroc can be decreased when combined with Dronedarone.Approved, Investigational
MebendazoleThe metabolism of Mebendazole can be decreased when combined with Dronedarone.Approved, Vet Approved
MedetomidineDronedarone may decrease the vasoconstricting activities of Medetomidine.Vet Approved
Medical CannabisThe metabolism of Medical Cannabis can be decreased when combined with Dronedarone.Experimental, Investigational
Medroxyprogesterone acetateThe metabolism of Medroxyprogesterone acetate can be decreased when combined with Dronedarone.Approved, Investigational
MefloquineMefloquine may increase the QTc-prolonging activities of Dronedarone.Approved, Investigational
MeloxicamThe metabolism of Meloxicam can be decreased when combined with Dronedarone.Approved, Vet Approved
MentholThe risk or severity of hypotension can be increased when Dronedarone is combined with Menthol.Approved
MephentermineDronedarone may decrease the vasoconstricting activities of Mephentermine.Approved
MephenytoinThe metabolism of Mephenytoin can be decreased when combined with Dronedarone.Investigational, Withdrawn
MepindololDronedarone may increase the bradycardic activities of Mepindolol.Experimental
MequitazineThe metabolism of Mequitazine can be decreased when combined with Dronedarone.Approved
MesoridazineThe metabolism of Mesoridazine can be decreased when combined with Dronedarone.Approved, Investigational
MetaraminolDronedarone may decrease the vasoconstricting activities of Metaraminol.Approved, Investigational
MetergolineThe risk or severity of adverse effects can be increased when Metergoline is combined with Dronedarone.Experimental
MethadoneMethadone may increase the QTc-prolonging activities of Dronedarone.Approved
MethamphetamineThe metabolism of Methamphetamine can be decreased when combined with Dronedarone.Approved, Illicit
MethaqualoneThe metabolism of Methaqualone can be decreased when combined with Dronedarone.Illicit, Withdrawn
MethotrimeprazineMethotrimeprazine may increase the antihypertensive activities of Dronedarone.Approved, Investigational
MethoxamineDronedarone may decrease the vasoconstricting activities of Methoxamine.Approved, Investigational
MethoxsalenThe metabolism of Methoxsalen can be decreased when combined with Dronedarone.Approved
MethoxyfluraneThe metabolism of Methoxyflurane can be decreased when combined with Dronedarone.Approved, Investigational, Vet Approved
MethoxyphenamineDronedarone may decrease the vasoconstricting activities of Methoxyphenamine.Experimental
MethsuximideThe risk or severity of hypotension can be increased when Dronedarone is combined with Methsuximide.Approved
MethyldopaMethyldopa may increase the bradycardic activities of Dronedarone.Approved
MethylergometrineThe risk or severity of adverse effects can be increased when Methylergometrine is combined with Dronedarone.Approved
MethylphenidateThe metabolism of Methylphenidate can be decreased when combined with Dronedarone.Approved, Investigational
MethylprednisoloneThe metabolism of Methylprednisolone can be decreased when combined with Dronedarone.Approved, Vet Approved
MethyltestosteroneThe metabolism of Methyltestosterone can be decreased when combined with Dronedarone.Approved
MethyprylonThe metabolism of Methyprylon can be decreased when combined with Dronedarone.Approved, Illicit, Withdrawn
MethysergideThe risk or severity of adverse effects can be increased when Methysergide is combined with Dronedarone.Approved
MetipranololDronedarone may increase the bradycardic activities of Metipranolol.Approved
MetoclopramideMetoclopramide may increase the QTc-prolonging activities of Dronedarone.Approved, Investigational
MetoprololThe serum concentration of Metoprolol can be increased when it is combined with Dronedarone.Approved, Investigational
MetronidazoleMetronidazole may increase the QTc-prolonging activities of Dronedarone.Approved
MevastatinThe serum concentration of Mevastatin can be increased when it is combined with Dronedarone.Experimental
MexiletineThe metabolism of Mexiletine can be decreased when combined with Dronedarone.Approved, Investigational
MianserinThe metabolism of Mianserin can be decreased when combined with Dronedarone.Approved, Investigational
MibefradilThe metabolism of Mibefradil can be decreased when combined with Dronedarone.Investigational, Withdrawn
MiconazoleThe metabolism of Miconazole can be decreased when combined with Dronedarone.Approved, Investigational, Vet Approved
MidazolamThe metabolism of Midazolam can be decreased when combined with Dronedarone.Approved, Illicit
MidecamycinThe metabolism of Midecamycin can be decreased when combined with Dronedarone.Approved
MidodrineDronedarone may decrease the vasoconstricting activities of Midodrine.Approved
MidostaurinThe metabolism of Dronedarone can be decreased when combined with Midostaurin.Approved, Investigational
MifepristoneDronedarone may increase the QTc-prolonging activities of Mifepristone.Approved, Investigational
MinaprineThe metabolism of Minaprine can be decreased when combined with Dronedarone.Approved
MirabegronMirabegron may increase the QTc-prolonging activities of Dronedarone.Approved
MirodenafilMirodenafil may increase the hypotensive activities of Dronedarone.Investigational
MirtazapineMirtazapine may increase the QTc-prolonging activities of Dronedarone.Approved
MitotaneThe serum concentration of Dronedarone can be decreased when it is combined with Mitotane.Approved
MoclobemideThe metabolism of Moclobemide can be decreased when combined with Dronedarone.Approved, Investigational
ModafinilThe metabolism of Modafinil can be decreased when combined with Dronedarone.Approved, Investigational
MoexiprilMoexipril may increase the QTc-prolonging activities of Dronedarone.Approved
MontelukastThe metabolism of Montelukast can be decreased when combined with Dronedarone.Approved
MorphineThe metabolism of Morphine can be decreased when combined with Dronedarone.Approved, Investigational
MoxifloxacinMoxifloxacin may increase the QTc-prolonging activities of Dronedarone.Approved, Investigational
MoxonidineDronedarone may decrease the vasoconstricting activities of Moxonidine.Approved, Investigational
Mycophenolate mofetilThe metabolism of Mycophenolate mofetil can be decreased when combined with Dronedarone.Approved, Investigational
NabiximolsThe metabolism of Nabiximols can be decreased when combined with Dronedarone.Approved, Investigational
NadololDronedarone may increase the bradycardic activities of Nadolol.Approved
NaftopidilThe risk or severity of hypotension can be increased when Dronedarone is combined with Naftopidil.Investigational
NaloxegolThe serum concentration of Naloxegol can be increased when it is combined with Dronedarone.Approved
NaloxoneThe metabolism of Naloxone can be decreased when combined with Dronedarone.Approved, Vet Approved
NaphazolineDronedarone may decrease the vasoconstricting activities of Naphazoline.Approved
NateglinideThe metabolism of Nateglinide can be decreased when combined with Dronedarone.Approved, Investigational
NebivololDronedarone may increase the bradycardic activities of Nebivolol.Approved, Investigational
NefazodoneThe serum concentration of Dronedarone can be increased when it is combined with Nefazodone.Approved, Withdrawn
NelfinavirThe serum concentration of Dronedarone can be increased when it is combined with Nelfinavir.Approved
NeratinibThe metabolism of Neratinib can be decreased when combined with Dronedarone.Approved, Investigational
NetupitantThe serum concentration of Dronedarone can be increased when it is combined with Netupitant.Approved, Investigational
NevirapineThe serum concentration of Dronedarone can be decreased when it is combined with Nevirapine.Approved
NicardipineDronedarone may increase the antihypertensive activities of Nicardipine.Approved, Investigational
NicergolineThe risk or severity of adverse effects can be increased when Nicergoline is combined with Dronedarone.Approved, Investigational
NicotineThe metabolism of Nicotine can be decreased when combined with Dronedarone.Approved
NifedipineThe metabolism of Nifedipine can be decreased when combined with Dronedarone.Approved
NiguldipineDronedarone may increase the antihypertensive activities of Niguldipine.Experimental
NilotinibThe risk or severity of QTc prolongation can be increased when Dronedarone is combined with Nilotinib.Approved, Investigational
NiludipineThe risk or severity of hypotension can be increased when Dronedarone is combined with Niludipine.Experimental
NilvadipineThe metabolism of Nilvadipine can be decreased when combined with Dronedarone.Approved, Investigational
NimesulideThe risk or severity of hypotension can be increased when Dronedarone is combined with Nimesulide.Approved, Investigational, Withdrawn
NimodipineThe serum concentration of Nimodipine can be increased when it is combined with Dronedarone.Approved, Investigational
NintedanibThe serum concentration of Nintedanib can be increased when it is combined with Dronedarone.Approved
NisoldipineThe metabolism of Nisoldipine can be decreased when combined with Dronedarone.Approved
NitrazepamThe metabolism of Nitrazepam can be decreased when combined with Dronedarone.Approved
NitrendipineThe metabolism of Nitrendipine can be decreased when combined with Dronedarone.Approved, Investigational
NitrofuralThe metabolism of Nitrofural can be decreased when combined with Dronedarone.Approved, Investigational, Vet Approved
NorepinephrineDronedarone may decrease the vasoconstricting activities of Norepinephrine.Approved
NorethisteroneThe metabolism of Norethisterone can be decreased when combined with Dronedarone.Approved
NorfenefrineDronedarone may decrease the vasoconstricting activities of Norfenefrine.Experimental
NorfloxacinNorfloxacin may increase the QTc-prolonging activities of Dronedarone.Approved
NorgestrelThe metabolism of Norgestrel can be decreased when combined with Dronedarone.Approved
NortriptylineDronedarone may increase the antihypertensive activities of Nortriptyline.Approved
NylidrinDronedarone may decrease the vasoconstricting activities of Nylidrin.Approved
OctopamineDronedarone may decrease the vasoconstricting activities of Octopamine.Experimental
OctreotideOctreotide may increase the QTc-prolonging activities of Dronedarone.Approved, Investigational
OdanacatibThe metabolism of Odanacatib can be decreased when combined with Dronedarone.Investigational
OfloxacinOfloxacin may increase the QTc-prolonging activities of Dronedarone.Approved
OlanzapineDronedarone may increase the antihypertensive activities of Olanzapine.Approved, Investigational
OlaparibThe serum concentration of Olaparib can be increased when it is combined with Dronedarone.Approved
OlodaterolOlodaterol may increase the QTc-prolonging activities of Dronedarone.Approved
OlopatadineThe metabolism of Olopatadine can be decreased when combined with Dronedarone.Approved
OmeprazoleThe metabolism of Omeprazole can be decreased when combined with Dronedarone.Approved, Investigational, Vet Approved
OndansetronOndansetron may increase the QTc-prolonging activities of Dronedarone.Approved
OpiumThe metabolism of Opium can be decreased when combined with Dronedarone.Approved, Illicit
OrciprenalineDronedarone may decrease the vasoconstricting activities of Orciprenaline.Approved
OrphenadrineThe metabolism of Orphenadrine can be decreased when combined with Dronedarone.Approved
OsimertinibThe serum concentration of Dronedarone can be increased when it is combined with Osimertinib.Approved
OspemifeneThe metabolism of Ospemifene can be decreased when combined with Dronedarone.Approved, Investigational
OtiloniumThe risk or severity of hypotension can be increased when Dronedarone is combined with Otilonium.Experimental, Investigational
OxazepamThe metabolism of Oxazepam can be decreased when combined with Dronedarone.Approved
OxprenololDronedarone may increase the bradycardic activities of Oxprenolol.Approved
OxybutyninThe metabolism of Oxybutynin can be decreased when combined with Dronedarone.Approved, Investigational
OxycodoneThe risk or severity of adverse effects can be increased when Dronedarone is combined with Oxycodone.Approved, Illicit, Investigational
OxyfedrineDronedarone may decrease the vasoconstricting activities of Oxyfedrine.Experimental
OxymetazolineDronedarone may decrease the vasoconstricting activities of Oxymetazoline.Approved, Investigational
OxymorphoneThe metabolism of Oxymorphone can be decreased when combined with Dronedarone.Approved, Investigational, Vet Approved
OxytocinOxytocin may increase the QTc-prolonging activities of Dronedarone.Approved, Vet Approved
PaclitaxelThe metabolism of Paclitaxel can be decreased when combined with Dronedarone.Approved, Vet Approved
PalbociclibThe serum concentration of Dronedarone can be increased when it is combined with Palbociclib.Approved, Investigational
PaliperidoneThe risk or severity of QTc prolongation can be increased when Paliperidone is combined with Dronedarone.Approved
PalonosetronThe metabolism of Palonosetron can be decreased when combined with Dronedarone.Approved, Investigational
PanobinostatThe serum concentration of Dronedarone can be increased when it is combined with Panobinostat.Approved, Investigational
PantoprazoleThe metabolism of Pantoprazole can be decreased when combined with Dronedarone.Approved
ParamethadioneThe metabolism of Paramethadione can be decreased when combined with Dronedarone.Approved
ParamethasoneThe metabolism of Paramethasone can be decreased when combined with Dronedarone.Approved
ParecoxibThe metabolism of Parecoxib can be decreased when combined with Dronedarone.Approved
ParicalcitolThe metabolism of Paricalcitol can be decreased when combined with Dronedarone.Approved, Investigational
ParitaprevirThe metabolism of Paritaprevir can be decreased when combined with Dronedarone.Approved, Investigational
ParoxetineThe metabolism of Dronedarone can be decreased when combined with Paroxetine.Approved, Investigational
PasireotidePasireotide may increase the QTc-prolonging activities of Dronedarone.Approved
PazopanibThe serum concentration of Pazopanib can be increased when it is combined with Dronedarone.Approved
Peginterferon alfa-2bThe serum concentration of Dronedarone can be decreased when it is combined with Peginterferon alfa-2b.Approved
PenbutololDronedarone may increase the bradycardic activities of Penbutolol.Approved, Investigational
PentamidinePentamidine may increase the QTc-prolonging activities of Dronedarone.Approved, Investigational
PentobarbitalThe serum concentration of Dronedarone can be decreased when it is combined with Pentobarbital.Approved, Investigational, Vet Approved
PentoxifyllinePentoxifylline may increase the hypotensive activities of Dronedarone.Approved, Investigational
PerampanelThe metabolism of Perampanel can be decreased when combined with Dronedarone.Approved
PerflutrenPerflutren may increase the QTc-prolonging activities of Dronedarone.Approved
PergolideThe risk or severity of adverse effects can be increased when Pergolide is combined with Dronedarone.Approved, Investigational, Vet Approved, Withdrawn
PerhexilineThe metabolism of Perhexiline can be decreased when combined with Dronedarone.Approved, Investigational
PermethrinThe metabolism of Permethrin can be decreased when combined with Dronedarone.Approved, Investigational
PerospironeThe metabolism of Perospirone can be decreased when combined with Dronedarone.Approved
PerphenazineThe metabolism of Perphenazine can be decreased when combined with Dronedarone.Approved
PethidineThe metabolism of Pethidine can be decreased when combined with Dronedarone.Approved
PhenacetinThe metabolism of Phenacetin can be decreased when combined with Dronedarone.Withdrawn
PhendimetrazineDronedarone may decrease the vasoconstricting activities of Phendimetrazine.Approved, Illicit
PhenforminThe metabolism of Phenformin can be decreased when combined with Dronedarone.Approved, Investigational, Withdrawn
PhenindioneThe serum concentration of Phenindione can be increased when it is combined with Dronedarone.Approved, Investigational
PhenobarbitalThe serum concentration of Dronedarone can be decreased when it is combined with Phenobarbital.Approved, Investigational
PhenoxybenzaminePhenoxybenzamine may increase the antihypertensive activities of Dronedarone.Approved
PhenprocoumonThe serum concentration of Phenprocoumon can be increased when it is combined with Dronedarone.Approved, Investigational
PhentolamineDronedarone may increase the antihypertensive activities of Phentolamine.Approved
PhenylephrineDronedarone may decrease the vasoconstricting activities of Phenylephrine.Approved
PhenylpropanolamineDronedarone may decrease the vasoconstricting activities of Phenylpropanolamine.Approved, Vet Approved, Withdrawn
PhenytoinThe serum concentration of Dronedarone can be decreased when it is combined with Phenytoin.Approved, Vet Approved
PilocarpineThe metabolism of Pilocarpine can be decreased when combined with Dronedarone.Approved, Investigational
PimecrolimusThe metabolism of Pimecrolimus can be decreased when combined with Dronedarone.Approved, Investigational
PimozideThe serum concentration of Pimozide can be increased when it is combined with Dronedarone.Approved
PinacidilThe metabolism of Pinacidil can be decreased when combined with Dronedarone.Approved
PinaveriumThe risk or severity of hypotension can be increased when Dronedarone is combined with Pinaverium.Approved
PindololDronedarone may increase the bradycardic activities of Pindolol.Approved, Investigational
PioglitazoneThe metabolism of Pioglitazone can be decreased when combined with Dronedarone.Approved, Investigational
PiperaquineThe metabolism of Piperaquine can be decreased when combined with Dronedarone.Approved, Investigational
PiperazineThe metabolism of Piperazine can be decreased when combined with Dronedarone.Approved, Vet Approved
PipotiazineThe metabolism of Pipotiazine can be decreased when combined with Dronedarone.Approved, Investigational
PirbuterolDronedarone may decrease the vasoconstricting activities of Pirbuterol.Approved
PitavastatinThe serum concentration of Pitavastatin can be increased when it is combined with Dronedarone.Approved
PitolisantThe serum concentration of Pitolisant can be increased when it is combined with Dronedarone.Approved, Investigational
PizotifenDronedarone may increase the antihypertensive activities of Pizotifen.Approved
Platelet Activating FactorDronedarone may increase the bradycardic activities of Platelet Activating Factor.Experimental
PodofiloxThe metabolism of Podofilox can be decreased when combined with Dronedarone.Approved
PomalidomideThe metabolism of Pomalidomide can be decreased when combined with Dronedarone.Approved
PonatinibThe metabolism of Ponatinib can be decreased when combined with Dronedarone.Approved, Investigational
Poractant alfaDronedarone may increase the bradycardic activities of Poractant alfa.Approved
PosaconazoleThe serum concentration of Dronedarone can be increased when it is combined with Posaconazole.Approved, Investigational, Vet Approved
PractololDronedarone may increase the bradycardic activities of Practolol.Approved
PrasteroneThe metabolism of Prasterone can be decreased when combined with Dronedarone.Approved, Investigational, Nutraceutical
PrasugrelThe metabolism of Prasugrel can be decreased when combined with Dronedarone.Approved
PravastatinThe serum concentration of Pravastatin can be increased when it is combined with Dronedarone.Approved
PrazepamThe metabolism of Prazepam can be decreased when combined with Dronedarone.Approved, Illicit
PraziquantelThe metabolism of Praziquantel can be decreased when combined with Dronedarone.Approved, Investigational, Vet Approved
PrazosinPrazosin may increase the antihypertensive activities of Dronedarone.Approved
PrednisoloneThe metabolism of Prednisolone can be decreased when combined with Dronedarone.Approved, Vet Approved
PrednisoneThe metabolism of Prednisone can be decreased when combined with Dronedarone.Approved, Vet Approved
PrenalterolDronedarone may decrease the vasoconstricting activities of Prenalterol.Experimental
PrenylamineThe risk or severity of hypotension can be increased when Dronedarone is combined with Prenylamine.Withdrawn
PrimaquinePrimaquine may increase the QTc-prolonging activities of Dronedarone.Approved
PrimidoneThe serum concentration of Dronedarone can be decreased when it is combined with Primidone.Approved, Vet Approved
ProcainamideThe risk or severity of QTc prolongation can be increased when Procainamide is combined with Dronedarone.Approved
ProcaterolDronedarone may decrease the vasoconstricting activities of Procaterol.Approved, Investigational
ProchlorperazineThe metabolism of Prochlorperazine can be decreased when combined with Dronedarone.Approved, Vet Approved
ProgesteroneThe metabolism of Progesterone can be decreased when combined with Dronedarone.Approved, Vet Approved
ProguanilThe metabolism of Proguanil can be decreased when combined with Dronedarone.Approved
PromazinePromazine may increase the QTc-prolonging activities of Dronedarone.Approved, Vet Approved
PromethazinePromethazine may increase the QTc-prolonging activities of Dronedarone.Approved, Investigational
PropafenonePropafenone may increase the arrhythmogenic activities of Dronedarone.Approved
PropericiazineDronedarone may increase the antihypertensive activities of Propericiazine.Approved, Investigational
PropiomazinePropiomazine may increase the antihypertensive activities of Dronedarone.Approved
PropiverineDronedarone may increase the antihypertensive activities of Propiverine.Approved, Investigational
PropofolPropofol may increase the QTc-prolonging activities of Dronedarone.Approved, Investigational, Vet Approved
PropranololDronedarone may increase the bradycardic activities of Propranolol.Approved, Investigational
ProtokylolDronedarone may decrease the vasoconstricting activities of Protokylol.Approved, Vet Approved
ProtriptylineProtriptyline may increase the QTc-prolonging activities of Dronedarone.Approved
PrucaloprideThe serum concentration of Prucalopride can be increased when it is combined with Dronedarone.Approved
PseudoephedrineThe metabolism of Pseudoephedrine can be decreased when combined with Dronedarone.Approved
PyrazinamideThe metabolism of Pyrazinamide can be decreased when combined with Dronedarone.Approved, Investigational
QuazepamThe metabolism of Quazepam can be decreased when combined with Dronedarone.Approved, Illicit
QuetiapineThe risk or severity of QTc prolongation can be increased when Quetiapine is combined with Dronedarone.Approved
QuinacrineThe metabolism of Quinacrine can be decreased when combined with Dronedarone.Approved, Investigational
QuinidineThe risk or severity of QTc prolongation can be increased when Quinidine is combined with Dronedarone.Approved, Investigational
QuinineThe risk or severity of QTc prolongation can be increased when Quinine is combined with Dronedarone.Approved
RabeprazoleThe metabolism of Rabeprazole can be decreased when combined with Dronedarone.Approved, Investigational
RacepinephrineDronedarone may increase the antihypertensive activities of Racepinephrine.Approved
RactopamineDronedarone may decrease the vasoconstricting activities of Ractopamine.Vet Approved
RaloxifeneThe metabolism of Raloxifene can be decreased when combined with Dronedarone.Approved, Investigational
RamelteonThe metabolism of Ramelteon can be decreased when combined with Dronedarone.Approved, Investigational
RanitidineThe metabolism of Ranitidine can be decreased when combined with Dronedarone.Approved
RanolazineThe serum concentration of Ranolazine can be increased when it is combined with Dronedarone.Approved, Investigational
ReboxetineThe metabolism of Reboxetine can be decreased when combined with Dronedarone.Approved, Investigational
RegorafenibThe metabolism of Regorafenib can be decreased when combined with Dronedarone.Approved
RemoxiprideThe metabolism of Remoxipride can be decreased when combined with Dronedarone.Approved, Withdrawn
RepaglinideThe metabolism of Repaglinide can be decreased when combined with Dronedarone.Approved, Investigational
RepinotanThe metabolism of Repinotan can be decreased when combined with Dronedarone.Investigational
ReproterolDronedarone may decrease the vasoconstricting activities of Reproterol.Investigational
RetapamulinThe metabolism of Retapamulin can be decreased when combined with Dronedarone.Approved
RibociclibThe risk or severity of QTc prolongation can be increased when Ribociclib is combined with Dronedarone.Approved, Investigational
RifabutinThe serum concentration of Dronedarone can be decreased when it is combined with Rifabutin.Approved, Investigational
RifampicinThe serum concentration of Dronedarone can be decreased when it is combined with Rifampicin.Approved
RifapentineThe serum concentration of Dronedarone can be decreased when it is combined with Rifapentine.Approved, Investigational
RifaximinThe serum concentration of Rifaximin can be increased when it is combined with Dronedarone.Approved, Investigational
RilmenidineDronedarone may decrease the vasoconstricting activities of Rilmenidine.Approved, Investigational
RilpivirineThe serum concentration of Rilpivirine can be increased when it is combined with Dronedarone.Approved
RimiterolDronedarone may decrease the vasoconstricting activities of Rimiterol.Experimental
RimonabantThe metabolism of Rimonabant can be decreased when combined with Dronedarone.Approved, Investigational
RiociguatThe metabolism of Riociguat can be decreased when combined with Dronedarone.Approved
RisperidoneRisperidone may increase the antihypertensive activities of Dronedarone.Approved, Investigational
RitobegronDronedarone may decrease the vasoconstricting activities of Ritobegron.Investigational
RitodrineDronedarone may decrease the vasoconstricting activities of Ritodrine.Approved, Investigational
RitonavirThe metabolism of Dronedarone can be decreased when combined with Ritonavir.Approved, Investigational
RivaroxabanThe metabolism of Rivaroxaban can be decreased when combined with Dronedarone.Approved
RivastigmineRivastigmine may increase the bradycardic activities of Dronedarone.Approved, Investigational
RofecoxibThe metabolism of Rofecoxib can be decreased when combined with Dronedarone.Approved, Investigational, Withdrawn
RolapitantThe metabolism of Rolapitant can be decreased when combined with Dronedarone.Approved, Investigational
RomidepsinThe metabolism of Romidepsin can be decreased when combined with Dronedarone.Approved, Investigational
RomifidineDronedarone may decrease the vasoconstricting activities of Romifidine.Vet Approved
RopiniroleThe metabolism of Ropinirole can be decreased when combined with Dronedarone.Approved, Investigational
RopivacaineThe metabolism of Ropivacaine can be decreased when combined with Dronedarone.Approved
RosuvastatinThe serum concentration of Rosuvastatin can be increased when it is combined with Dronedarone.Approved
RotigotineThe metabolism of Rotigotine can be decreased when combined with Dronedarone.Approved
RoxithromycinThe metabolism of Roxithromycin can be decreased when combined with Dronedarone.Approved, Investigational, Withdrawn
RucaparibThe metabolism of Rucaparib can be decreased when combined with Dronedarone.Approved, Investigational
RupatadineThe metabolism of Rupatadine can be decreased when combined with Dronedarone.Approved
RuxolitinibRuxolitinib may increase the bradycardic activities of Dronedarone.Approved
SafinamideThe metabolism of Safinamide can be decreased when combined with Dronedarone.Approved, Investigational
SalbutamolSalbutamol may increase the QTc-prolonging activities of Dronedarone.Approved, Vet Approved
SalmeterolThe serum concentration of Salmeterol can be increased when it is combined with Dronedarone.Approved
SaquinavirThe serum concentration of Dronedarone can be increased when it is combined with Saquinavir.Approved, Investigational
SarilumabThe therapeutic efficacy of Dronedarone can be decreased when used in combination with Sarilumab.Approved, Investigational
SaxagliptinThe serum concentration of Saxagliptin can be increased when it is combined with Dronedarone.Approved
SelegilineThe metabolism of Selegiline can be decreased when combined with Dronedarone.Approved, Investigational, Vet Approved
SeletracetamThe risk or severity of hypotension can be increased when Dronedarone is combined with Seletracetam.Investigational
SelexipagThe metabolism of Selexipag can be decreased when combined with Dronedarone.Approved
SeratrodastThe metabolism of Seratrodast can be decreased when combined with Dronedarone.Approved
SertindoleThe metabolism of Sertindole can be decreased when combined with Dronedarone.Approved, Investigational, Withdrawn
SertralineSertraline may increase the QTc-prolonging activities of Dronedarone.Approved
SevofluraneSevoflurane may increase the QTc-prolonging activities of Dronedarone.Approved, Vet Approved
SibutramineThe metabolism of Sibutramine can be decreased when combined with Dronedarone.Approved, Illicit, Investigational, Withdrawn
SildenafilSildenafil may increase the hypotensive activities of Dronedarone.Approved, Investigational
SilodosinThe serum concentration of Silodosin can be increased when it is combined with Dronedarone.Approved
SiltuximabThe serum concentration of Dronedarone can be decreased when it is combined with Siltuximab.Approved, Investigational
SimeprevirThe serum concentration of Dronedarone can be increased when it is combined with Simeprevir.Approved
SimvastatinThe serum concentration of Simvastatin can be increased when it is combined with Dronedarone.Approved
SirolimusThe metabolism of Sirolimus can be decreased when combined with Dronedarone.Approved, Investigational
SitagliptinThe metabolism of Sitagliptin can be decreased when combined with Dronedarone.Approved, Investigational
SolabegronDronedarone may decrease the vasoconstricting activities of Solabegron.Investigational
SolifenacinSolifenacin may increase the QTc-prolonging activities of Dronedarone.Approved
SonidegibThe serum concentration of Sonidegib can be increased when it is combined with Dronedarone.Approved, Investigational
SorafenibSorafenib may increase the QTc-prolonging activities of Dronedarone.Approved, Investigational
SotalolDronedarone may increase the bradycardic activities of Sotalol.Approved
SparteineThe metabolism of Sparteine can be decreased when combined with Dronedarone.Experimental
SpiramycinThe metabolism of Spiramycin can be decreased when combined with Dronedarone.Approved
St. John's WortThe serum concentration of Dronedarone can be decreased when it is combined with St. John's Wort.Approved, Investigational, Nutraceutical
StiripentolThe serum concentration of Dronedarone can be increased when it is combined with Stiripentol.Approved
SufentanilThe metabolism of Sufentanil can be decreased when combined with Dronedarone.Approved, Investigational
SulfadiazineThe metabolism of Sulfadiazine can be decreased when combined with Dronedarone.Approved, Investigational, Vet Approved
SulfamethoxazoleSulfamethoxazole may increase the QTc-prolonging activities of Dronedarone.Approved
SulfinpyrazoneThe metabolism of Sulfinpyrazone can be decreased when combined with Dronedarone.Approved
SulfisoxazoleSulfisoxazole may increase the QTc-prolonging activities of Dronedarone.Approved, Vet Approved
SunitinibSunitinib may increase the QTc-prolonging activities of Dronedarone.Approved, Investigational
SuvorexantThe serum concentration of Suvorexant can be increased when it is combined with Dronedarone.Approved, Investigational
SynephrineDronedarone may decrease the vasoconstricting activities of Synephrine.Experimental
Synthetic Conjugated Estrogens, AThe metabolism of Synthetic Conjugated Estrogens, A can be decreased when combined with Dronedarone.Approved
Synthetic Conjugated Estrogens, BThe metabolism of Synthetic Conjugated Estrogens, B can be decreased when combined with Dronedarone.Approved
TacrolimusTacrolimus may increase the QTc-prolonging activities of Dronedarone.Approved, Investigational
TadalafilTadalafil may increase the hypotensive activities of Dronedarone.Approved, Investigational
TalinololDronedarone may increase the bradycardic activities of Talinolol.Investigational
TamoxifenThe serum concentration of the active metabolites of Tamoxifen can be reduced when Tamoxifen is used in combination with Dronedarone resulting in a loss in efficacy.Approved
TamsulosinTamsulosin may increase the antihypertensive activities of Dronedarone.Approved, Investigational
TapentadolThe metabolism of Tapentadol can be decreased when combined with Dronedarone.Approved
TasosartanThe metabolism of Tasosartan can be decreased when combined with Dronedarone.Approved
Taurochenodeoxycholic acidThe metabolism of Taurochenodeoxycholic acid can be decreased when combined with Dronedarone.Experimental
TegaserodThe metabolism of Tegaserod can be decreased when combined with Dronedarone.Approved, Investigational, Withdrawn
TelaprevirThe serum concentration of Dronedarone can be increased when it is combined with Telaprevir.Approved, Withdrawn
TelavancinTelavancin may increase the QTc-prolonging activities of Dronedarone.Approved
TelithromycinThe serum concentration of Dronedarone can be increased when it is combined with Telithromycin.Approved
TemazepamThe metabolism of Temazepam can be decreased when combined with Dronedarone.Approved, Investigational
TemsirolimusThe metabolism of Temsirolimus can be decreased when combined with Dronedarone.Approved
TeniposideThe metabolism of Teniposide can be decreased when combined with Dronedarone.Approved
TerazosinTerazosin may increase the antihypertensive activities of Dronedarone.Approved
TerbinafineThe metabolism of Dronedarone can be decreased when combined with Terbinafine.Approved, Investigational, Vet Approved
TerbutalineDronedarone may increase the bradycardic activities of Terbutaline.Approved
TerfenadineThe metabolism of Terfenadine can be decreased when combined with Dronedarone.Approved, Withdrawn
TergurideThe risk or severity of adverse effects can be increased when Terguride is combined with Dronedarone.Experimental
TerodilineThe risk or severity of hypotension can be increased when Dronedarone is combined with Terodiline.Experimental
TertatololDronedarone may increase the bradycardic activities of Tertatolol.Experimental
TesmilifeneThe metabolism of Tesmilifene can be decreased when combined with Dronedarone.Investigational
TestosteroneThe metabolism of Testosterone can be decreased when combined with Dronedarone.Approved, Investigational
Testosterone cypionateThe metabolism of Testosterone cypionate can be decreased when combined with Dronedarone.Approved
Testosterone enanthateThe metabolism of Testosterone enanthate can be decreased when combined with Dronedarone.Approved
Testosterone propionateThe metabolism of Testosterone propionate can be decreased when combined with Dronedarone.Approved, Investigational, Vet Approved, Withdrawn
Testosterone undecanoateThe metabolism of Testosterone undecanoate can be decreased when combined with Dronedarone.Approved, Investigational
TetrabenazineThe risk or severity of QTc prolongation can be increased when Tetrabenazine is combined with Dronedarone.Approved, Investigational
TetracyclineThe metabolism of Tetracycline can be decreased when combined with Dronedarone.Approved, Vet Approved
TetrahydropalmatineThe risk or severity of hypotension can be increased when Dronedarone is combined with Tetrahydropalmatine.Investigational
TetryzolineDronedarone may decrease the vasoconstricting activities of Tetryzoline.Approved
TezacaftorThe metabolism of Tezacaftor can be decreased when combined with Dronedarone.Approved, Investigational
TheophyllineTheophylline may increase the hypotensive activities of Dronedarone.Approved
ThioproperazineDronedarone may increase the antihypertensive activities of Thioproperazine.Approved
ThioridazineThe serum concentration of Thioridazine can be increased when it is combined with Dronedarone.Approved, Withdrawn
ThiotepaThe metabolism of Thiotepa can be decreased when combined with Dronedarone.Approved, Investigational
ThiothixeneThiothixene may increase the QTc-prolonging activities of Dronedarone.Approved
TiagabineThe metabolism of Tiagabine can be decreased when combined with Dronedarone.Approved, Investigational
TicagrelorThe metabolism of Ticagrelor can be decreased when combined with Dronedarone.Approved
TiclopidineThe metabolism of Dronedarone can be decreased when combined with Ticlopidine.Approved
TimololDronedarone may increase the bradycardic activities of Timolol.Approved
TinidazoleThe metabolism of Tinidazole can be decreased when combined with Dronedarone.Approved, Investigational
TioclomarolThe serum concentration of Tioclomarol can be increased when it is combined with Dronedarone.Experimental
TiotropiumThe metabolism of Tiotropium can be decreased when combined with Dronedarone.Approved
TipranavirThe metabolism of Dronedarone can be decreased when combined with Tipranavir.Approved, Investigational
TizanidineTizanidine may increase the QTc-prolonging activities of Dronedarone.Approved, Investigational
TocilizumabThe serum concentration of Dronedarone can be decreased when it is combined with Tocilizumab.Approved
TocofersolanThe metabolism of Tocofersolan can be decreased when combined with Dronedarone.Approved
TocopherolThe metabolism of Tocopherol can be decreased when combined with Dronedarone.Approved, Investigational
TofacitinibTofacitinib may increase the bradycardic activities of Dronedarone.Approved, Investigational
TolazolineTolazoline may increase the antihypertensive activities of Dronedarone.Approved, Vet Approved
Tolfenamic AcidThe risk or severity of hypotension can be increased when Dronedarone is combined with Tolfenamic Acid.Approved, Investigational
TolterodineTolterodine may increase the QTc-prolonging activities of Dronedarone.Approved, Investigational
TolvaptanThe serum concentration of Tolvaptan can be increased when it is combined with Dronedarone.Approved
TopotecanThe serum concentration of Topotecan can be increased when it is combined with Dronedarone.Approved, Investigational
ToremifeneThe risk or severity of QTc prolongation can be increased when Toremifene is combined with Dronedarone.Approved, Investigational
TrabectedinThe metabolism of Trabectedin can be decreased when combined with Dronedarone.Approved, Investigational
TramadolThe therapeutic efficacy of Tramadol can be decreased when used in combination with Dronedarone.Approved, Investigational
TranilastThe risk or severity of hypotension can be increased when Dronedarone is combined with Tranilast.Approved, Investigational
TranylcypromineThe metabolism of Dronedarone can be decreased when combined with Tranylcypromine.Approved, Investigational
Trastuzumab emtansineThe metabolism of Trastuzumab emtansine can be decreased when combined with Dronedarone.Approved, Investigational
TrazodoneTrazodone may increase the antihypertensive activities of Dronedarone.Approved, Investigational
TreprostinilTreprostinil may increase the QTc-prolonging activities of Dronedarone.Approved, Investigational
TretinoinThe metabolism of Tretinoin can be decreased when combined with Dronedarone.Approved, Investigational, Nutraceutical
TretoquinolDronedarone may decrease the vasoconstricting activities of Tretoquinol.Experimental
TriamcinoloneThe metabolism of Triamcinolone can be decreased when combined with Dronedarone.Approved, Vet Approved
TriazolamThe metabolism of Triazolam can be decreased when combined with Dronedarone.Approved, Investigational
TrifluoperazineTrifluoperazine may increase the antihypertensive activities of Dronedarone.Approved, Investigational
TrimazosinTrimazosin may increase the antihypertensive activities of Dronedarone.Experimental
TrimebutineThe risk or severity of hypotension can be increased when Dronedarone is combined with Trimebutine.Approved
TrimethadioneThe metabolism of Trimethadione can be decreased when combined with Dronedarone.Approved
TrimethoprimTrimethoprim may increase the QTc-prolonging activities of Dronedarone.Approved, Vet Approved
TrimipramineDronedarone may increase the antihypertensive activities of Trimipramine.Approved
TriptorelinTriptorelin may increase the QTc-prolonging activities of Dronedarone.Approved, Vet Approved
TroglitazoneThe metabolism of Troglitazone can be decreased when combined with Dronedarone.Investigational, Withdrawn
TroleandomycinThe metabolism of Troleandomycin can be decreased when combined with Dronedarone.Approved
TulobuterolDronedarone may decrease the vasoconstricting activities of Tulobuterol.Investigational
UdenafilUdenafil may increase the hypotensive activities of Dronedarone.Approved, Investigational
UlipristalThe serum concentration of Ulipristal can be increased when it is combined with Dronedarone.Approved
UmeclidiniumThe metabolism of Umeclidinium can be decreased when combined with Dronedarone.Approved
UrapidilUrapidil may increase the antihypertensive activities of Dronedarone.Investigational
ValbenazineThe metabolism of Valbenazine can be decreased when combined with Dronedarone.Approved, Investigational
ValdecoxibThe metabolism of Valdecoxib can be decreased when combined with Dronedarone.Approved, Investigational, Withdrawn
VandetanibThe risk or severity of QTc prolongation can be increased when Dronedarone is combined with Vandetanib.Approved
VanoxerineThe metabolism of Vanoxerine can be decreased when combined with Dronedarone.Investigational
VardenafilVardenafil may increase the QTc-prolonging activities of Dronedarone.Approved
VelpatasvirThe metabolism of Velpatasvir can be decreased when combined with Dronedarone.Approved, Investigational
VemurafenibThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Dronedarone.Approved
VenetoclaxThe metabolism of Venetoclax can be decreased when combined with Dronedarone.Approved, Investigational
VenlafaxineVenlafaxine may increase the QTc-prolonging activities of Dronedarone.Approved
VerapamilVerapamil may increase the atrioventricular blocking (AV block) activities of Dronedarone.Approved
VernakalantThe metabolism of Vernakalant can be decreased when combined with Dronedarone.Approved, Investigational
VicrivirocThe metabolism of Vicriviroc can be decreased when combined with Dronedarone.Investigational
VilanterolVilanterol may increase the QTc-prolonging activities of Dronedarone.Approved
VilazodoneThe serum concentration of Vilazodone can be increased when it is combined with Dronedarone.Approved
VinblastineThe metabolism of Vinblastine can be decreased when combined with Dronedarone.Approved
VincristineThe metabolism of Vincristine can be decreased when combined with Dronedarone.Approved, Investigational
VindesineThe serum concentration of Vindesine can be increased when it is combined with Dronedarone.Approved, Investigational
VinflunineThe metabolism of Vinflunine can be decreased when combined with Dronedarone.Approved, Investigational
VinorelbineThe metabolism of Vinorelbine can be decreased when combined with Dronedarone.Approved, Investigational
VinpocetineThe risk or severity of hypotension can be increased when Dronedarone is combined with Vinpocetine.Investigational
VismodegibThe metabolism of Vismodegib can be decreased when combined with Dronedarone.Approved, Investigational
VoriconazoleThe serum concentration of Dronedarone can be increased when it is combined with Voriconazole.Approved, Investigational
VorinostatVorinostat may increase the QTc-prolonging activities of Dronedarone.Approved, Investigational
VortioxetineThe metabolism of Vortioxetine can be decreased when combined with Dronedarone.Approved, Investigational
VoxilaprevirThe metabolism of Voxilaprevir can be decreased when combined with Dronedarone.Approved, Investigational
WarfarinThe serum concentration of Warfarin can be increased when it is combined with Dronedarone.Approved
WIN 55212-2The risk or severity of hypotension can be increased when Dronedarone is combined with WIN 55212-2.Experimental
XamoterolDronedarone may decrease the vasoconstricting activities of Xamoterol.Experimental
XylazineDronedarone may decrease the vasoconstricting activities of Xylazine.Vet Approved
XylometazolineDronedarone may decrease the vasoconstricting activities of Xylometazoline.Approved, Investigational
YohimbineThe metabolism of Yohimbine can be decreased when combined with Dronedarone.Approved, Investigational, Vet Approved
ZafirlukastThe metabolism of Zafirlukast can be decreased when combined with Dronedarone.Approved, Investigational
ZalcitabineThe metabolism of Zalcitabine can be decreased when combined with Dronedarone.Approved, Investigational
ZaleplonThe metabolism of Zaleplon can be decreased when combined with Dronedarone.Approved, Illicit, Investigational
ZiconotideThe risk or severity of hypotension can be increased when Dronedarone is combined with Ziconotide.Approved
ZidovudineThe metabolism of Zidovudine can be decreased when combined with Dronedarone.Approved
ZileutonThe metabolism of Zileuton can be decreased when combined with Dronedarone.Approved, Investigational, Withdrawn
ZiprasidoneThe risk or severity of QTc prolongation can be increased when Ziprasidone is combined with Dronedarone.Approved
ZolpidemThe metabolism of Zolpidem can be decreased when combined with Dronedarone.Approved
ZomepiracThe metabolism of Zomepirac can be decreased when combined with Dronedarone.Withdrawn
ZonisamideThe metabolism of Zonisamide can be decreased when combined with Dronedarone.Approved, Investigational
ZopicloneThe serum concentration of Zopiclone can be increased when it is combined with Dronedarone.Approved
ZotepineThe metabolism of Zotepine can be decreased when combined with Dronedarone.Approved, Investigational, Withdrawn
ZuclopenthixolThe serum concentration of Zuclopenthixol can be increased when it is combined with Dronedarone.Approved, Investigational
Food Interactions
  • Absorption of dronedarone increases 3-fold if taken with food especially if meal is high in fat content
  • Do not take dronedarone with grapefruit juice. Grapefruit juice is a potent CYP3A4 inhibitor which will increase serum concentrations of dronedarone threefold

References

Synthesis Reference

Arie Gutman, Gennadi Nisnevich, Lev Yudovitch, "Process for the preparation of dronedarone." U.S. Patent US20050049302, issued March 03, 2005.

US20050049302
General References
  1. Dale KM, White CM: Dronedarone: an amiodarone analog for the treatment of atrial fibrillation and atrial flutter. Ann Pharmacother. 2007 Apr;41(4):599-605. Epub 2007 Mar 27. [PubMed:17389667]
  2. Iwamoto T, Watanabe Y, Kita S, Blaustein MP: Na+/Ca2+ exchange inhibitors: a new class of calcium regulators. Cardiovasc Hematol Disord Drug Targets. 2007 Sep;7(3):188-98. [PubMed:17896959]
  3. Celestino D, Medei E, Moro S, Elizari MV, Sicouri S: Acute in vitro effects of dronedarone, an iodine-free derivative, and amiodarone, on the rabbit sinoatrial node automaticity: a comparative study. J Cardiovasc Pharmacol Ther. 2007 Sep;12(3):248-57. [PubMed:17875953]
  4. Pamukcu B, Lip GY: Dronedarone as a new treatment option for atrial fibrillation patients: pharmacokinetics, pharmacodynamics and clinical practice. Expert Opin Pharmacother. 2011 Jan;12(1):131-40. doi: 10.1517/14656566.2011.540800. Epub 2010 Dec 2. [PubMed:21126199]
  5. De Ferrari GM, Dusi V: Drug safety evaluation of dronedarone in atrial fibrillation. Expert Opin Drug Saf. 2012 Nov;11(6):1023-45. doi: 10.1517/14740338.2012.722994. Epub 2012 Sep 13. [PubMed:22971242]
External Links
KEGG Drug
D02537
PubChem Compound
208898
PubChem Substance
175426865
ChemSpider
180996
BindingDB
50151864
ChEBI
50659
ChEMBL
CHEMBL184412
PharmGKB
PA153619853
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Dronedarone
ATC Codes
C01BD07 — Dronedarone
AHFS Codes
  • 24:04.04.20 — Class III Antiarrythmics
FDA label
Download (606 KB)
MSDS
Download (115 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
2CompletedTreatmentNonvalvular Atrial Fibrillation1
3CompletedPreventionAtrial Flutter / Nonvalvular Atrial Fibrillation1
3CompletedPreventionNonvalvular Atrial Fibrillation1
3CompletedTreatmentAtrial Flutter / Nonvalvular Atrial Fibrillation2
3CompletedTreatmentNonvalvular Atrial Fibrillation2
3TerminatedTreatmentCongestive Heart Failure (CHF)1
3TerminatedTreatmentNonvalvular Atrial Fibrillation1
4CompletedTreatmentNonvalvular Atrial Fibrillation3
4TerminatedTreatmentNonvalvular Atrial Fibrillation3
4Unknown StatusTreatmentParoxysmal Atrial Fibrillation (PAF)1
Not AvailableActive Not RecruitingTreatmentNonvalvular Atrial Fibrillation / Quality of Life1
Not AvailableCompletedTreatmentNonvalvular Atrial Fibrillation1
Not AvailableRecruitingTreatmentNonvalvular Atrial Fibrillation1
Not AvailableUnknown StatusTreatmentDRONEDARONE / ICD SHOCKS / ICDs1
Not AvailableUnknown StatusTreatmentNonvalvular Atrial Fibrillation1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
FormRouteStrength
TabletOral400 mg
Tablet, film coatedOral400 mg/1
Tablet, film coatedOral400 mg
Prices
Not Available
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
CA2294812No2009-09-292018-06-19Canada
CA2047773No2000-09-122011-07-24Canada
US5223510No1996-07-262016-07-26Us
US8410167No2009-04-162029-04-16Us
US8602215No2011-06-302031-06-30Us
US9107900No2009-04-162029-04-16Us
US8318800No1998-06-192018-06-19Us
US7323493No1998-06-192018-06-19Us

Properties

State
Solid
Experimental Properties
PropertyValueSource
water solubilityInsoluble FDA label
logP7.346MSDS
Predicted Properties
PropertyValueSource
Water Solubility0.00201 mg/mLALOGPS
logP6.46ALOGPS
logP5.28ChemAxon
logS-5.4ALOGPS
pKa (Strongest Acidic)9.08ChemAxon
pKa (Strongest Basic)9.79ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area88.85 Å2ChemAxon
Rotatable Bond Count17ChemAxon
Refractivity158.13 m3·mol-1ChemAxon
Polarizability66.05 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability0ChemAxon
Rule of FiveNoChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+1.0
Blood Brain Barrier+0.9156
Caco-2 permeable-0.6057
P-glycoprotein substrateSubstrate0.6265
P-glycoprotein inhibitor IInhibitor0.7879
P-glycoprotein inhibitor IINon-inhibitor0.5218
Renal organic cation transporterNon-inhibitor0.7334
CYP450 2C9 substrateNon-substrate0.7339
CYP450 2D6 substrateNon-substrate0.7682
CYP450 3A4 substrateSubstrate0.6963
CYP450 1A2 substrateNon-inhibitor0.5487
CYP450 2C9 inhibitorInhibitor0.6209
CYP450 2D6 inhibitorNon-inhibitor0.8299
CYP450 2C19 inhibitorNon-inhibitor0.5319
CYP450 3A4 inhibitorNon-inhibitor0.5198
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.8288
Ames testNon AMES toxic0.5248
CarcinogenicityNon-carcinogens0.6132
BiodegradationNot ready biodegradable1.0
Rat acute toxicity2.6273 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Strong inhibitor0.8036
hERG inhibition (predictor II)Inhibitor0.8051
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-QTOF , negativeLC-MS/MSsplash10-0a4i-0000090000-8897a71d0d4436083f2f
LC-MS/MS Spectrum - LC-ESI-QTOF , negativeLC-MS/MSsplash10-0a4i-0000090000-0412b5e5e921a14ade8e
LC-MS/MS Spectrum - LC-ESI-QTOF , negativeLC-MS/MSsplash10-0a4i-0000090000-77777b7e67d24302cc61
LC-MS/MS Spectrum - LC-ESI-QTOF , negativeLC-MS/MSsplash10-0a4i-0000090000-98e3b8bdab6f810350d0
LC-MS/MS Spectrum - LC-ESI-QTOF , negativeLC-MS/MSsplash10-0a4i-0009020000-46fc09138b4d4c98f7db
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-0a4i-0000090000-5fc376f78fcd143923df
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-0a4i-0000090000-a4ea4fac6f54cdcb7cbc
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-0a4i-0000090000-c3aef714c9268fa971ca
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-0a4i-0100290000-55925fc920832a562317
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-052o-0922440000-21a75dc14e4f6eec2a80
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-000i-0011920000-b36c2c2ac812fdf862c0
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0a4i-0000090000-6af26e1e5383a4521666
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0a4i-0000090000-8a1e04d2d220b7c178b7
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0udl-1900000000-1526ae7b1c72d66d17f7
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0zfr-3900000000-5720b31639362bc77d45
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0pb9-6900000000-5862d8b2fbe4b55544fd
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0a4i-9800000000-52425d2c67f0ee9e6833
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0a4i-0000090000-91af4261328f04d47762
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0a4i-0000090000-e6261075748cb68a6673
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0udl-1900000000-b6ee80d1389866275d10
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0zfr-3900000000-79bd8a4d5fb81c2d7697
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0zfr-6900000000-45b09ec3acdb68cc2d94
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0a4i-9810000000-e53f3747472fb6644b74
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-000i-0011920000-32cc8203ba76ec3246f7

Taxonomy

Description
This compound belongs to the class of organic compounds known as aryl-phenylketones. These are aromatic compounds containing a ketone substituted by one aryl group, and a phenyl group.
Kingdom
Organic compounds
Super Class
Organic oxygen compounds
Class
Organooxygen compounds
Sub Class
Carbonyl compounds
Direct Parent
Aryl-phenylketones
Alternative Parents
Sulfanilides / Benzofurans / 3-aroylfurans / Benzoyl derivatives / Phenol ethers / Phenoxy compounds / Alkyl aryl ethers / Organic sulfonamides / Organosulfonamides / Heteroaromatic compounds
show 6 more
Substituents
Aryl-phenylketone / Sulfanilide / Benzofuran / Phenoxy compound / Benzoyl / Phenol ether / 3-aroylfuran / Alkyl aryl ether / Monocyclic benzene moiety / Organic sulfonic acid amide
show 21 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
tertiary amino compound, aromatic ether, sulfonamide, 1-benzofurans, aromatic ketone (CHEBI:50659)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Protein heterodimerization activity
Specific Function
This alpha-adrenergic receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. Its effect is mediated by G(q) and G(11) prot...
Gene Name
ADRA1A
Uniprot ID
P35348
Uniprot Name
Alpha-1A adrenergic receptor
Molecular Weight
51486.005 Da
References
  1. Dale KM, White CM: Dronedarone: an amiodarone analog for the treatment of atrial fibrillation and atrial flutter. Ann Pharmacother. 2007 Apr;41(4):599-605. Epub 2007 Mar 27. [PubMed:17389667]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Protein heterodimerization activity
Specific Function
This alpha-adrenergic receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. Its effect is mediated by G(q) and G(11) prot...
Gene Name
ADRA1B
Uniprot ID
P35368
Uniprot Name
Alpha-1B adrenergic receptor
Molecular Weight
56835.375 Da
References
  1. Dale KM, White CM: Dronedarone: an amiodarone analog for the treatment of atrial fibrillation and atrial flutter. Ann Pharmacother. 2007 Apr;41(4):599-605. Epub 2007 Mar 27. [PubMed:17389667]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Alpha1-adrenergic receptor activity
Specific Function
This alpha-adrenergic receptor mediates its effect through the influx of extracellular calcium.
Gene Name
ADRA1D
Uniprot ID
P25100
Uniprot Name
Alpha-1D adrenergic receptor
Molecular Weight
60462.205 Da
References
  1. Dale KM, White CM: Dronedarone: an amiodarone analog for the treatment of atrial fibrillation and atrial flutter. Ann Pharmacother. 2007 Apr;41(4):599-605. Epub 2007 Mar 27. [PubMed:17389667]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Thioesterase binding
Specific Function
Alpha-2 adrenergic receptors mediate the catecholamine-induced inhibition of adenylate cyclase through the action of G proteins. The rank order of potency for agonists of this receptor is oxymetazo...
Gene Name
ADRA2A
Uniprot ID
P08913
Uniprot Name
Alpha-2A adrenergic receptor
Molecular Weight
48956.275 Da
References
  1. Dale KM, White CM: Dronedarone: an amiodarone analog for the treatment of atrial fibrillation and atrial flutter. Ann Pharmacother. 2007 Apr;41(4):599-605. Epub 2007 Mar 27. [PubMed:17389667]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Epinephrine binding
Specific Function
Alpha-2 adrenergic receptors mediate the catecholamine-induced inhibition of adenylate cyclase through the action of G proteins. The rank order of potency for agonists of this receptor is clonidine...
Gene Name
ADRA2B
Uniprot ID
P18089
Uniprot Name
Alpha-2B adrenergic receptor
Molecular Weight
49565.8 Da
References
  1. Dale KM, White CM: Dronedarone: an amiodarone analog for the treatment of atrial fibrillation and atrial flutter. Ann Pharmacother. 2007 Apr;41(4):599-605. Epub 2007 Mar 27. [PubMed:17389667]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Protein homodimerization activity
Specific Function
Alpha-2 adrenergic receptors mediate the catecholamine-induced inhibition of adenylate cyclase through the action of G proteins.
Gene Name
ADRA2C
Uniprot ID
P18825
Uniprot Name
Alpha-2C adrenergic receptor
Molecular Weight
49521.585 Da
References
  1. Dale KM, White CM: Dronedarone: an amiodarone analog for the treatment of atrial fibrillation and atrial flutter. Ann Pharmacother. 2007 Apr;41(4):599-605. Epub 2007 Mar 27. [PubMed:17389667]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Receptor signaling protein activity
Specific Function
Beta-adrenergic receptors mediate the catecholamine-induced activation of adenylate cyclase through the action of G proteins. This receptor binds epinephrine and norepinephrine with approximately e...
Gene Name
ADRB1
Uniprot ID
P08588
Uniprot Name
Beta-1 adrenergic receptor
Molecular Weight
51322.1 Da
References
  1. Dale KM, White CM: Dronedarone: an amiodarone analog for the treatment of atrial fibrillation and atrial flutter. Ann Pharmacother. 2007 Apr;41(4):599-605. Epub 2007 Mar 27. [PubMed:17389667]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Voltage-gated potassium channel activity involved in ventricular cardiac muscle cell action potential repolarization
Specific Function
Pore-forming (alpha) subunit of voltage-gated inwardly rectifying potassium channel. Channel properties are modulated by cAMP and subunit assembly. Mediates the rapidly activating component of the ...
Gene Name
KCNH2
Uniprot ID
Q12809
Uniprot Name
Potassium voltage-gated channel subfamily H member 2
Molecular Weight
126653.52 Da
References
  1. Iwamoto T, Watanabe Y, Kita S, Blaustein MP: Na+/Ca2+ exchange inhibitors: a new class of calcium regulators. Cardiovasc Hematol Disord Drug Targets. 2007 Sep;7(3):188-98. [PubMed:17896959]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Voltage-gated calcium channel activity
Specific Function
Voltage-sensitive calcium channels (VSCC) mediate the entry of calcium ions into excitable cells and are also involved in a variety of calcium-dependent processes, including muscle contraction, hor...
Gene Name
CACNA1C
Uniprot ID
Q13936
Uniprot Name
Voltage-dependent L-type calcium channel subunit alpha-1C
Molecular Weight
248974.1 Da
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Voltage-gated calcium channel activity involved sa node cell action potential
Specific Function
Voltage-sensitive calcium channels (VSCC) mediate the entry of calcium ions into excitable cells and are also involved in a variety of calcium-dependent processes, including muscle contraction, hor...
Gene Name
CACNA1D
Uniprot ID
Q01668
Uniprot Name
Voltage-dependent L-type calcium channel subunit alpha-1D
Molecular Weight
245138.75 Da
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Voltage-gated calcium channel activity
Specific Function
Voltage-sensitive calcium channels (VSCC) mediate the entry of calcium ions into excitable cells and are also involved in a variety of calcium-dependent processes, including muscle contraction, hor...
Gene Name
CACNA1F
Uniprot ID
O60840
Uniprot Name
Voltage-dependent L-type calcium channel subunit alpha-1F
Molecular Weight
220675.9 Da
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Voltage-gated calcium channel activity
Specific Function
Voltage-sensitive calcium channels (VSCC) mediate the entry of calcium ions into excitable cells and are also involved in a variety of calcium-dependent processes, including muscle contraction, hor...
Gene Name
CACNA1S
Uniprot ID
Q13698
Uniprot Name
Voltage-dependent L-type calcium channel subunit alpha-1S
Molecular Weight
212348.1 Da
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Voltage-gated calcium channel activity
Specific Function
The beta subunit of voltage-dependent calcium channels contributes to the function of the calcium channel by increasing peak calcium current, shifting the voltage dependencies of activation and ina...
Gene Name
CACNB1
Uniprot ID
Q02641
Uniprot Name
Voltage-dependent L-type calcium channel subunit beta-1
Molecular Weight
65712.995 Da
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Voltage-gated calcium channel activity
Specific Function
The beta subunit of voltage-dependent calcium channels contributes to the function of the calcium channel by increasing peak calcium current, shifting the voltage dependencies of activation and ina...
Gene Name
CACNB2
Uniprot ID
Q08289
Uniprot Name
Voltage-dependent L-type calcium channel subunit beta-2
Molecular Weight
73579.925 Da
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Voltage-gated calcium channel activity
Specific Function
The beta subunit of voltage-dependent calcium channels contributes to the function of the calcium channel by increasing peak calcium current, shifting the voltage dependencies of activation and ina...
Gene Name
CACNB3
Uniprot ID
P54284
Uniprot Name
Voltage-dependent L-type calcium channel subunit beta-3
Molecular Weight
54531.425 Da
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Voltage-gated calcium channel activity
Specific Function
The beta subunit of voltage-dependent calcium channels contributes to the function of the calcium channel by increasing peak calcium current, shifting the voltage dependencies of activation and ina...
Gene Name
CACNB4
Uniprot ID
O00305
Uniprot Name
Voltage-dependent L-type calcium channel subunit beta-4
Molecular Weight
58168.625 Da
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Voltage-gated sodium channel activity
Specific Function
Mediates the voltage-dependent sodium ion permeability of excitable membranes. Assuming opened or closed conformations in response to the voltage difference across the membrane, the protein forms a...
Gene Name
SCN1A
Uniprot ID
P35498
Uniprot Name
Sodium channel protein type 1 subunit alpha
Molecular Weight
228969.49 Da
References
  1. Lalevee N, Nargeot J, Barrere-Lemaire S, Gautier P, Richard S: Effects of amiodarone and dronedarone on voltage-dependent sodium current in human cardiomyocytes. J Cardiovasc Electrophysiol. 2003 Aug;14(8):885-90. [PubMed:12890054]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Potassium ion leak channel activity
Specific Function
Ion channel that contributes to passive transmembrane potassium transport (PubMed:23169818). Reversibly converts between a voltage-insensitive potassium leak channel and a voltage-dependent outward...
Gene Name
KCNK2
Uniprot ID
O95069
Uniprot Name
Potassium channel subfamily K member 2
Molecular Weight
47092.215 Da
References
  1. Schmidt C, Wiedmann F, Schweizer PA, Becker R, Katus HA, Thomas D: Novel electrophysiological properties of dronedarone: inhibition of human cardiac two-pore-domain potassium (K2P) channels. Naunyn Schmiedebergs Arch Pharmacol. 2012 Oct;385(10):1003-16. doi: 10.1007/s00210-012-0780-9. Epub 2012 Jul 13. [PubMed:22790794]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
References
  1. Dorian P: Clinical pharmacology of dronedarone: implications for the therapy of atrial fibrillation. J Cardiovasc Pharmacol Ther. 2010 Dec;15(4 Suppl):15S-8S. doi: 10.1177/1074248410367792. Epub 2010 May 14. [PubMed:20472816]
  2. Schafer JA, Kjesbo NK, Gleason PP: Dronedarone: current evidence and future questions. Cardiovasc Ther. 2010 Spring;28(1):38-47. doi: 10.1111/j.1755-5922.2009.00112.x. [PubMed:20074258]
  3. De Ferrari GM, Dusi V: Drug safety evaluation of dronedarone in atrial fibrillation. Expert Opin Drug Saf. 2012 Nov;11(6):1023-45. doi: 10.1517/14740338.2012.722994. Epub 2012 Sep 13. [PubMed:22971242]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic...
Gene Name
CYP2D6
Uniprot ID
P10635
Uniprot Name
Cytochrome P450 2D6
Molecular Weight
55768.94 Da
References
  1. Schafer JA, Kjesbo NK, Gleason PP: Dronedarone: current evidence and future questions. Cardiovasc Ther. 2010 Spring;28(1):38-47. doi: 10.1111/j.1755-5922.2009.00112.x. [PubMed:20074258]
  2. De Ferrari GM, Dusi V: Drug safety evaluation of dronedarone in atrial fibrillation. Expert Opin Drug Saf. 2012 Nov;11(6):1023-45. doi: 10.1517/14740338.2012.722994. Epub 2012 Sep 13. [PubMed:22971242]

Carriers

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Toxic substance binding
Specific Function
Serum albumin, the main protein of plasma, has a good binding capacity for water, Ca(2+), Na(+), K(+), fatty acids, hormones, bilirubin and drugs. Its main function is the regulation of the colloid...
Gene Name
ALB
Uniprot ID
P02768
Uniprot Name
Serum albumin
Molecular Weight
69365.94 Da

Transporters

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Xenobiotic-transporting atpase activity
Specific Function
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name
ABCB1
Uniprot ID
P08183
Uniprot Name
Multidrug resistance protein 1
Molecular Weight
141477.255 Da
References
  1. De Ferrari GM, Dusi V: Drug safety evaluation of dronedarone in atrial fibrillation. Expert Opin Drug Saf. 2012 Nov;11(6):1023-45. doi: 10.1517/14740338.2012.722994. Epub 2012 Sep 13. [PubMed:22971242]
  2. Schafer JA, Kjesbo NK, Gleason PP: Dronedarone: current evidence and future questions. Cardiovasc Ther. 2010 Spring;28(1):38-47. doi: 10.1111/j.1755-5922.2009.00112.x. [PubMed:20074258]

Drug created on October 18, 2007 17:47 / Updated on July 16, 2018 21:23